Composition for enhancing immune function or preventing, ameliorating or treating obesity or metabolic disease comprising acorus gramineus solander extract or fraction thereof as active ingredient
The Seokchangpo extract or fraction, rich in polysaccharides and flavonoids, addresses the limitations of existing treatments by enhancing immune function, preventing obesity and metabolic diseases, and treating leaky gut syndrome through its prebiotic activity, offering a safe and effective solution for improving immune function and intestinal health.
Patent Information
- Application Number
- PCT/KR2024/006688
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-21
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-21
AI Technical Summary
Current solutions fail to effectively enhance immune function, prevent or treat obesity and metabolic diseases, and address leaky gut syndrome, with existing treatments often having side effects or limited efficacy.
A composition containing an extract or fraction of Seokchangpo, derived from Acorus gramineus, which includes polysaccharides and flavonoids, is used to improve immune function, prevent obesity and metabolic diseases, and treat leaky gut syndrome by promoting beneficial intestinal bacteria and reducing harmful bacteria, thereby improving the intestinal environment.
The Seokchangpo extract or fraction demonstrates non-toxicity and long-term immune function enhancement, suppresses weight gain and metabolic disease indicators, and restores the intestinal environment by promoting beneficial bacteria and reducing permeability, effectively addressing obesity, metabolic diseases, and leaky gut syndrome without side effects.
Smart Images

Figure KR2024006688_21112024_PF_FP_ABST
Abstract
Description
A composition for enhancing immune function, or for preventing, improving, or treating obesity or metabolic diseases, containing an extract of Seokchangpo or a fraction thereof as an active ingredient
[0001] The present invention relates to a composition for enhancing immune function, or for preventing, improving, or treating obesity or metabolic disease, a prebiotic composition, or a composition for preventing, improving, or treating leaky gut syndrome, comprising an extract of Seokchangpo as an active ingredient.
[0002] Acorus gramineus Solander, the dried rhizome of Acorus gramineus, a perennial herb in the Araceae family, has long been used to treat various ailments such as digestive problems, depression, epilepsy, and central nervous system disorders. In Oriental medicine, Acorus gramineus is said to be mild in nature and pungent in flavor, and to be beneficial to the heart and stomach meridians. It is also known to treat spleen symptoms caused by wind-cold and dampness, and to have the effects of strengthening the stomach and invigorating blood vessels, regulating the circulation of qi, circulating blood, relieving wind, and eliminating dampness. The main active ingredients of Acorus gramineus Solander are known to be β-asarone, caryophyllene, α-humulene, and sekishone. Modern pharmacology has shown that Acorus gramineus has sedative, antispasmodic, and antitussive effects, anti-dementia effects through memory enhancement, anti-stress effects, and anti-tumor effects. However, research on the various effects of Acorus gramineus is still insufficient.
[0003] As a result of repeated research on the above-mentioned Seokchangpo, the inventors of the present invention confirmed that the Seokchangpo extract and its fractions have effects such as enhancing immune function, improving or treating obesity or metabolic diseases, improving intestinal flora, and improving or treating leaky gut syndrome, thereby completing the present invention.
[0004] The purpose of the present invention is to provide a food composition for enhancing immune function or preventing or improving obesity or metabolic disease, which contains an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0005] Another object of the present invention is to provide a prebiotic composition comprising a Seokchangpo extract or a fraction thereof as an active ingredient.
[0006] Another object of the present invention is to provide a food composition for preventing or improving leaky gut syndrome, which comprises an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0007] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating diseases caused by decreased immunity, which comprises an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0008] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating obesity or metabolic disease, comprising an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0009] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating leaky gut syndrome, comprising an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0010] In order to achieve the above-mentioned purpose, the present invention provides a food composition for enhancing immune function or preventing or improving obesity or metabolic disease, which contains an extract of Seokchangpo or a fraction thereof as an effective ingredient.
[0011] According to one embodiment of the present invention, the Seokchangpo extract may be extracted with water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
[0012] According to one embodiment of the present invention, the Seokchangpo extract may contain 0.1% to 2.5% of dietary fiber.
[0013] According to one embodiment of the present invention, the acorn fraction may be a acorn-derived polysaccharide fraction.
[0014] According to one embodiment of the present invention, the polysaccharide fraction derived from the stone sap may include 20 to 35 wt% of neutral sugar, 1 to 10 wt% of acidic sugar, and 1 to 5 wt% of polyphenol relative to the total polysaccharide fraction.
[0015] According to one embodiment of the present invention, the polysaccharide fraction derived from Seokchangpo may further contain 1 to 5 wt% of flavonoids.
[0016] According to one embodiment of the present invention, the constituent sugars constituting the polysaccharide fraction derived from the stone sap may include 80 to 90 wt% of neutral sugar and 10 to 20 wt% of acidic sugar.
[0017] According to one embodiment of the present invention, the composition may include neutral sugar and acid sugar in a weight ratio of 1:0.1 to 1.
[0018] According to one embodiment of the present invention, the neutral sugar may be composed of fucose, rhamnose, arabinose, galactose, glucose, and xylose; and the acidic sugar may be composed of galacturonic acid and glucuronic acid.
[0019] According to one embodiment of the present invention, the arabinose and galactose may each be included in the constituent sugars at 20 to 30 wt%.
[0020] According to one embodiment of the present invention, the polysaccharide fraction derived from Seokchangpo may be prepared by a method comprising: (a) a step of mixing an extraction solvent with Seokchangpo powder and performing a first extraction at 70 to 100°C; (b) a step of precipitating the first extracted extract with a C1 to C4 alcohol and recovering the precipitate; and (c) a step of recovering a fraction having a molecular weight exceeding 12 kDa from the precipitate.
[0021] According to one embodiment of the present invention, the composition may be a prebiotic.
[0022] According to one embodiment of the present invention, the composition has a prebiotic activity that relatively increases beneficial intestinal bacteria compared to harmful intestinal bacteria, and the beneficial intestinal bacteria are at least one selected from the group consisting of Lactobacillus bulgaricus, Lactobalcillus gasseri, Bifidobacterium longum, and Bifidobacterium bifidum, and the harmful intestinal bacteria may be Escherichia coli.
[0023] According to one embodiment of the present invention, the composition may promote the proliferation of beneficial bacteria and the production of short-chain fatty acids (SCFAs) in a living intestine.
[0024] According to one embodiment of the present invention, the metabolic disease may be at least one selected from dyslipidemia, non-alcoholic fatty liver disease, insulin resistance syndrome, and diabetes.
[0025] In order to achieve the other objects mentioned above, the present invention provides a prebiotic composition comprising a Seokchangpo extract or a fraction thereof as an active ingredient.
[0026] In order to achieve another object mentioned above, the present invention provides a food composition for preventing or improving leaky gut syndrome, which comprises an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0027] According to one embodiment of the present invention, the composition may improve the intestinal environment damaged by a high-fat diet, restore intestinal beneficial microorganisms, reduce increased intestinal mucosal permeability, and restore reduced intestinal length.
[0028] In order to achieve another purpose mentioned above, the present invention provides a pharmaceutical composition for preventing or treating a disease caused by a decrease in immunity, which comprises an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0029] In order to achieve another purpose mentioned above, the present invention provides a pharmaceutical composition for preventing or treating obesity or metabolic disease, which comprises an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0030] In order to achieve another object mentioned above, the present invention provides a pharmaceutical composition for preventing or treating leaky gut syndrome, which comprises an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0031] The extract of Seokchangpo and its fractions of the present invention have the following effects.
[0032] a) It has excellent efficacy in enhancing immune function and is non-toxic, so it can improve immune function in the long term through daily diet and lifestyle habits.
[0033] b) It has the effect of suppressing the increase in body weight and body fat, suppressing the increase in blood sugar, reducing blood insulin concentration and HOMA-IR level, alleviating impaired glucose tolerance, reducing blood ALT and AST levels, blood triglyceride and total cholesterol concentration, and suppressing liver damage, so it can be effectively used for the prevention and treatment of metabolic diseases as well as obesity.
[0034] c) It selectively promotes the growth of beneficial intestinal microorganisms and promotes the production of beneficial components (short-chain fatty acids) from them, thereby improving the damaged intestinal environment of the host, restoring beneficial intestinal microorganisms, reducing increased intestinal mucosal permeability, and restoring reduced intestinal length, thereby improving, preventing, and treating leaky gut syndrome. In addition, by maintaining a slightly acidic intestinal environment, it can improve, suppress, and prevent intestinal infections caused by pathogenic bacteria.
[0035] Since the above-described Seokchangpo extract and its fractions of the present invention are natural-derived substances, there are no problems with side effects or cytotoxicity.
[0036] Figure 1 is a graph measuring cell viability for a polysaccharide fraction derived from the root of Seokchangpo prepared according to Example 1 of the present invention and a hot water extract of Seokchangpo root prepared according to Example 2.
[0037] FIG. 2 is a graph showing the amount of nitric oxide (NO) measured for a polysaccharide fraction derived from the root of Seokchangpo prepared according to Example 1 of the present invention and a hot water extract of Seokchangpo root prepared according to Example 2.
[0038] Figure 3 is a graph measuring the TNF-α production ability of a polysaccharide fraction derived from the root of Seokchangpo prepared according to Example 1 of the present invention and a hot water extract of Seokchangpo root prepared according to Example 2.
[0039] FIG. 4 is a graph measuring the IL-1β level for a polysaccharide fraction derived from the root of Atractylodes japonica prepared according to Example 1 of the present invention and a hot water extract of Atractylodes japonica prepared according to Example 2.
[0040] FIG. 5 is a graph measuring the IL-6 level for a polysaccharide fraction derived from the root of Atractylodes japonica prepared according to Example 1 of the invention and a hot water extract of Atractylodes japonica prepared according to Example 2.
[0041] FIG. 6A is a graph showing the results of measuring the average weight of animal models divided into Group 1 (NC, negative control group), Group 2 (HF, obese control group), Group 3 (FOS, positive control group), Group 4 (SFP5, 5 mg / kg administration group of the sample of Example 3), and Group 5 (SFP10, 10 mg / kg administration group of the sample of Example 3) for 8 weeks using a body composition analyzer (dual-energy X-ray absorptiometry).
[0042] Figure 6B is a photograph of the body shape of an animal model divided into Group 1 (NC, negative control group), Group 2 (HF, obese control group), Group 3 (FOS, positive control group), Group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and Group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3) measured using a body composition analyzer (dual-energy X-ray absorptiometry). In Figure 1b, the fat portion of the entire body shape is indicated in red.
[0043] Figure 6C is a graph showing the body fat mass (g) of animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3) measured using a body composition analyzer (dual-energy X-ray absorptiometry).
[0044] Figure 7A is a graph showing the results of measuring the weight of liver tissues extracted from animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3).
[0045] Figure 7B is a graph showing the results of measuring the weight of white epididymal fat tissue by extracting white epididymal fat tissue from animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3).
[0046] Figure 7C is a graph showing the results of measuring blood sugar concentrations in animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3).
[0047] Figure 7D is a graph showing the area under the blood glucose curve (AUC) according to the results of an oral glucose tolerance test (OGTT) of an animal model divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3).
[0048] FIG. 8A and FIG. 8B are graphs showing the blood ALT and AST concentrations of animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered with 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered with 10 mg / kg of the sample of Example 3), respectively, and FIG. 8C and FIG. 8D are graphs showing the blood triglyceride (TG) and total cholesterol (T-Chol) concentrations of animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered with 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered with 10 mg / kg of the sample of Example 3), respectively.
[0049] Figure 9a is a graph showing an image showing the degree of damage in liver tissue and an NAFLD activity score (NAFLD activity score, NAS) based on the images obtained by staining liver tissues extracted from animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3) after H&E staining.
[0050] Figure 9b is an image and graph showing the size of fat globules in epididymal fat tissue, obtained by staining with H&E after extracting epididymal fat tissue from animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3).
[0051] FIG. 10A is a graph showing the blood insulin concentration of an animal model divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, 5 mg / kg administration group of the sample of Example 3) and group 5 (SFP10, 10 mg / kg administration group of the sample of Example 3), and FIG. 10B is a graph showing the insulin resistance (HOMA-IR, Homeostatic Model Assessment for Insulin resistance) of an animal model divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, 5 mg / kg administration group of the sample of Example 3) and group 5 (SFP10, 10 mg / kg administration group of the sample of Example 3), and FIG. 10C is a graph showing the blood insulin concentration of an animal model divided into group 1 (NC, negative control group), group 2 (HF, This is a graph showing the blood leptin hormone concentration of animal models divided into 3 groups (obesity control group), 3 groups (FOS, positive control group), 4 groups (SFP5, group administered 5 mg / kg of the sample of Example 3), and 5 groups (SFP10, group administered 10 mg / kg of the sample of Example 3).
[0052] Figure 11 shows the results of analyzing the probiotic activity levels of glucose, FOS, and 15 kinds of food-derived extracts (cilantro, pawpaw leaves, grape skin, fig, green onion root, corn silk, ice plant, old pumpkin, eggplant, cucumber, lettuce, old pumpkin seeds, tomato, Acer monocarpa leaves, Acer monocarpa roots (Example 2)).
[0053] Figures 12 to 15 are graphs showing the prebiotics activity scores of experimental group 1 (0.1%), experimental group 2 (0.5%), positive control group (Inulin), and normal group (Normal) for Lactobacillus bulgaricus MG5167, Lactobalcillus gasseri MG4247, Bifidobacterium longum KCTC3421, or Bifidobacterium bifidum ACTC3440. Specifically, FIG. 12 shows the results for Lactobacillus bulgaricus MG5167, FIG. 13 shows the results for Lactobalcillus gasseri MG4247, FIG. 14 shows the results for Bifidobacterium longum KCTC3421, and FIG. 15 shows the results for Bifidobacterium bifidum ACTC3440.
[0054] Figure 16 is a graph showing the results of analyzing intestinal permeability for the negative control group (NC), high-fat diet group (HF), positive control group (PC), group 4 (Example 2, SFRE-50), and group 5 (Example 2, SFRE-100).
[0055] Figure 17 is a graph showing the results of measuring the intestinal pH of the negative control group (NC), high-fat diet group (HF), positive control group (PC), group 4 (Example 2, SFRE-50), and group 5 (Example 2, SFRE-100).
[0056] Figure 18 is a graph showing the results of measuring the intestinal length of the negative control group (NC), high-fat diet group (HF), positive control group (PC), group 4 (Example 2, SFRE-50), and group 5 (Example 2, SFRE-100).
[0057] Figure 19 is a graph showing the results of measuring the expression level of adhesion proteins in the intestinal tissues of the negative control group (NC), high-fat diet group (HF), positive control group (PC), group 4 (Example 2, SFRE-50), and group 5 (Example 2, SFRE-100) using Western blot.
[0058] Hereinafter, the present invention will be described in detail.
[0059] One aspect of the present invention relates to a food composition for enhancing immune function or preventing or improving obesity or metabolic disease, comprising an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0060] In this specification, “enhancing immune function” means all activities that enhance immune function, such as increasing NO production in immune cells and increasing cytokine production.
[0061] The Achyranthes root extract or its fraction of the present invention can prevent or improve diseases caused by a weakened immune system by enhancing immune function. These diseases may be selected from the group consisting of, but are not limited to, cancer, infectious diseases, inflammatory diseases, allergic diseases, colds, and chronic fatigue. Furthermore, even if the composition of the present invention does not target a specific disease, it can reduce the risk of infection and development of various bacterial and viral diseases by enhancing the body's overall immune function.
[0062] The extract of the present invention, or a fraction thereof, can activate macrophages and increase nitric oxide (NO) production. From an immune response perspective, an initial inflammatory response is required for immune cell activation and subsequent immunity enhancement. Therefore, contrary to anti-inflammatory effects, NO production actually plays a role in enhancing immune function.
[0063] The extract of Seokchangpo of the present invention or a fraction thereof can induce the activity of macrophages and significantly increase the secretion of one or more cytokines among IL-1β, IL-6, and TNF-α.
[0064] Macrophages secrete various cytokines during the process of engulfing and removing bacteria or foreign substances, thereby regulating immune phenomena. They are cells that play a central role in the immune response against antigens, and are involved in antigen presentation and non-specific immune responses of lymphocytes, and exhibit direct toxic activity against tumor cells. In addition, it is known that substances (LPS or natural products) that react with TLR (tool-like receptor) activate macrophages and produce cytokines such as IL-1, IL-6, IL-10, IL-12, and TNF-α, which can regulate secondary immune responses such as proliferation of T cells and B cells, activation of macrophages for phagocytosis, and defense against microbial infections.
[0065] In particular, IL-1β, IL-6, and TNF-α are representative cytokines induced by macrophages, and they play a central role in the inflammatory response following bacterial infection, and their amounts are known to increase in inflammatory lesions. IL-6 has been reported to act cooperatively with IL-1β to participate in the differentiation of T and B cells and to have anticancer effects, while TNF-α has cytotoxic and antiviral effects on specific cancer cells, and is known to play an important role in various biological responses that occur in acute and chronic inflammatory diseases.
[0066] In the present invention, 'obesity' does not simply mean being overweight, but a state in which body fat is excessively accumulated. This means that even if one appears to be of normal weight on the outside, if one's body fat percentage is high, one can be considered obese. The body mass index (BMI) is usually used to determine obesity. A BMI of 23 to 24.9 is considered overweight, 25 to 29.9 is considered mild obesity, 30 to 34.9 is considered moderate obesity, and 35 or more is considered severe obesity. Obesity is caused by a combination of factors rather than a single cause, including poor eating habits, including westernized eating habits, decreased activity level, emotional factors, and genetic factors. Obesity that occurs in this way ultimately increases the risk of chronic diseases such as hyperlipidemia, diabetes, and hypertension.
[0067] In the present invention, 'metabolic disease' means a condition or disease closely related to obesity or caused by obesity, and specifically may be at least one selected from the group consisting of dyslipidemia, non-alcoholic fatty liver disease, insulin resistance syndrome, and diabetes. The dyslipidemia may be at least one selected from the group consisting of hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. The fatty liver refers to a condition or disease in which fat accumulates in excessive amounts in liver cells due to a disorder of fat metabolism in the liver, and specifically may be non-alcoholic fatty liver disease.
[0068] In the present invention, hyperlipidemia refers to a condition or disease in which the concentration of fat components in the blood, particularly cholesterol or triglyceride, is higher than the normal level, and is used in a broad sense to include all conditions in which it is required to lower the concentration of lipids in the blood.
[0069] In the present invention, hypercholesterolemia means a condition or disease in which the cholesterol level in the blood is excessively high, and hypertriglyceridemia means a condition or disease in which the concentration of triglycerides in the blood is excessively high.
[0070] Specifically, the composition of the present invention can be said to be a composition that prevents, improves, alleviates, suppresses, and treats weight gain or body fat gain due to the various causes mentioned above. More preferably, it has the effect of preventing, improving, and treating obesity or metabolic diseases caused by a high-fat diet.
[0071] According to the experimental results of the present invention, when a high-fat diet is administered for a short or long period of time, body weight and body fat significantly increase. This leads to an increase in body weight, body fat, and white epididymal fat weight over time, and increases blood sugar, blood ALT and AST levels, blood triglycerides, and blood total cholesterol concentrations, as well as blood insulin concentrations and / or insulin resistance, and induces impaired glucose tolerance and / or liver damage, leading to obesity or metabolic disease.
[0072] According to the following examples, it can be confirmed that when the Achyranthes root extract of the present invention or a fraction thereof is administered, an increase in body weight, body fat, and white epididymal fat weight is suppressed, and blood sugar, blood ALT and AST levels, blood triglycerides, and blood total cholesterol levels are reduced, and blood insulin levels and / or an increase in insulin resistance are suppressed and lowered to normal levels. In addition, it can be confirmed that glucose tolerance impairment and / or liver damage are alleviated. Therefore, it can be seen that a composition containing the Achyranthes root extract of the present invention or a fraction thereof as an active ingredient has an effect of preventing, improving, or treating obesity or metabolic diseases.
[0073] In the present invention, 'Seokchangpo' is the root of Seokchangpo, and is significantly superior to extracts of Seokchangpo leaves, stems, flowers, or fruits in terms of immune function enhancement activity, prevention, improvement, or treatment activity for obesity or metabolic diseases, and proliferation activity for intestinal beneficial bacteria.
[0074] The above-mentioned Seokchangpo extract is an extract of the Seokchangpo root using water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof, and the extraction method need not be particularly limited. Preferably, the Seokchangpo root extract may be a Seokchangpo root hot water extract or a Seokchangpo root ethanol aqueous solution, for example, a Seokchangpo root alcohol extract. Most preferably, it may be a Seokchangpo root hot water extract.
[0075] In addition, the above-mentioned Seokchangpo root extract may be obtained by extracting Seokchangpo root with water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
[0076] In addition, the above-mentioned Achyranthes root extract may contain less than 2.5% of dietary fiber, preferably less than 0.1 to 2.5%, and may contain less than 2.0 to 2.5%. It can be confirmed that the above Achyranthes root extract exhibits a more remarkable prebiotic activity than conventional inulin and FOS despite containing a very low content of dietary fiber of less than 2.5% or 2.1%.
[0077] In the production of the above-mentioned Seokchangpo root extract, the Seokchangpo root used may be cut into a certain size, naturally dried in the shade or using a dryer, and then crushed. The drying period is not particularly limited as long as the moisture content of the Seokchangpo root is less than 10-20%.
[0078] In the present invention, the term "extract" includes not only a crude extract obtained by treating an extraction raw material with an extraction solvent, but also a processed product of the crude extract. For example, the extract of the root of Aquilegia japonica can be manufactured into a powder form through additional processes such as reduced pressure distillation and freeze drying or spray drying.
[0079] In addition, the term "extract" in the present invention also includes fractions obtained by further fractionating the crude extract. That is, the extract of the root of Aquilegia japonica includes not only those obtained using an extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, the extract may be purified through various additional methods, such as a polymer fraction obtained by passing it through an ultrafiltration membrane having a certain molecular weight cut-off value, or separation by various chromatographies (designed for separation according to size, charge, hydrophobicity, or affinity).
[0080] In the present invention, the acorn fraction may be a acorn-derived polysaccharide fraction.
[0081] The above-mentioned polysaccharide fraction of Seokchangpo may contain 20 to 35 wt% of neutral sugar, 1 to 10 wt% of uronic acid, and 1 to 5 wt% of polyphenol relative to the total polysaccharide fraction.
[0082] The neutral sugars are composed of arabinose, rhamnose, galactose, xylose, glucose, and fucose; the acidic sugars are composed of galacturonic acid and glucuronic acid.
[0083] Among the neutral sugars, arabinose is contained in an amount of 7 to 12 wt% and galactose is contained in an amount of 7 to 12 wt% relative to the total polysaccharide fraction, and thus has the highest proportion compared to other neutral sugars or acidic sugars contained in the polysaccharide fraction derived from the roots of Acorus coccinea of the present invention. In addition, rhamnose is contained in an amount of 1.0 to 3.0 wt%, xylose in an amount of 2 to 6 wt%, glucose in an amount of 3 to 6 wt%, and fucose in an amount of 0.1 to 0.3 wt%.
[0084] In addition, among the acidic sugars, galacturonic acid is contained in an amount of 3 to 7 wt% relative to the total polysaccharide fraction, which is a relatively high proportion compared to other neutral sugars or acidic sugars contained in the polysaccharide fraction derived from the roots of Seokchangpo of the present invention.
[0085] The polysaccharide fraction derived from the above-mentioned Seokchangpo may further contain 1 to 5 wt% of flavonoids.
[0086] In addition, the constituent sugars constituting the polysaccharide fraction derived from Seokchangpo of the present invention may include 80 to 90 wt% of neutral sugar and 10 to 20 wt% of acidic sugar.
[0087] In addition, the above-mentioned composition may include neutral sugars and acidic sugars in a weight ratio of 1:0.1 to 1, preferably 1:0.1 to 0.5, more preferably 1:0.1 to 0.3, more preferably 1:0.1 to 0.2, and even more preferably 1:0.15 to 0.2.
[0088] In addition, the polysaccharide fraction derived from Seokchangpo of the present invention may contain 20 to 30 wt% of the arabinose and galactose, respectively, in the constituent sugars.
[0089] In one specific example, the method for producing a polysaccharide fraction derived from the root of Seokchangpo of the present invention comprises the steps of (a) mixing Seokchangpo root and an extraction solvent and extracting at 70 to 100°C; and (b) precipitating the extracted extract with a C1 to C4 alcohol aqueous solution to recover a polysaccharide fraction derived from the root of Seokchangpo.
[0090] First, in the step (a), the powder of the root of Seokchangpo and the extraction solvent are mixed in a weight ratio of 1:10 to 50, and then extracted at 70 to 100°C for 2 to 8 hours, preferably 3 to 5 hours.
[0091] The above extraction solvent may include water, C1 to C4 alcohol, or a mixed solvent thereof. The water is not particularly limited, but examples thereof include groundwater, purified water, distilled water, and deionized water.
[0092] The above C1 to C4 alcohols need not be particularly limited, but examples thereof include methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, or normal-butanol.
[0093] The above mixed solvent does not need to be particularly limited, but preferably includes an aqueous solution of methanol, ethanol, butanol or propanol of 20 to 80% by volume.
[0094] Next, in the step (b), the extracted extract is precipitated with a C1 to C4 alcohol aqueous solution to recover a polysaccharide fraction derived from the root of Seokchangpo.
[0095] Specifically, a C1 to C4 alcohol aqueous solution is added to the above extract to a final concentration of 70 to 85%, and the polysaccharide is precipitated while standing at 4 to 20°C for 10 to 30 hours to obtain a polysaccharide fraction derived from the root of Seokchangpo.
[0096] The above C1 to C4 alcohol aqueous solution need not be particularly limited, but examples thereof include aqueous solutions of methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol or normal-butanol, and preferably an aqueous solution of ethanol.
[0097] In another specific example, the polysaccharide fraction derived from Aquilegia japonica of the present invention may be prepared by a method comprising: (a) mixing an extraction solvent with Aquilegia japonica root powder and performing a first extraction at 70 to 100°C; (b) precipitating the first extracted extract with a C1 to C4 alcohol and recovering the precipitate; and (c) recovering a fraction having a molecular weight exceeding 12 kDa from the precipitate.
[0098] Specifically, the step (a) is a step of mixing an extraction solvent with the Seokchangpo powder and performing a first extraction at 70 to 100°C, preferably 70 to 90°C. The extraction solvent may be water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof, and preferably water.
[0099] In the present invention, the acorn squash can be dried in the shade or using a dryer, and then crushed or used as is. The drying period is not particularly limited as long as the moisture content of the acorn squash is less than 20%.
[0100] The above-mentioned stone changpo and extraction solvent can be mixed and extracted in a volume ratio of 1:5 to 30, preferably in a volume ratio of 1:10 to 30, and more preferably in a volume ratio of 1:15 to 25.
[0101] After the above step (a), an additional step of removing residue may be performed. The method for removing the residue may be any known method, such as centrifugation or filtering, without particular limitation, and centrifugation is preferred.
[0102] Next, the step (b) is an alcohol precipitation step in which the first extracted extract is precipitated with a C1 to C4 alcohol to recover the precipitate. The alcohol precipitation may be performed using a known alcohol precipitation method, and the alcohol used in this process is preferably an alcohol having a concentration of 70% to 95% (v / v) mixed with water. The alcohol is preferably ethanol.
[0103] Next, the step (c) is a step of recovering a fraction having a molecular weight exceeding 12 kDa from the precipitate.
[0104] The method for recovering the above fraction is not particularly limited as long as it is a method for purifying based on molecular weight, but a method using dialysis is preferred. The dialysis may be performed for 0.5 to 5 days, and preferably for 1 to 3 days.
[0105] Afterwards, a step of freeze-drying the above-mentioned polysaccharide fraction of Seokdangpo can be added and performed.
[0106] The term "fraction" used herein when referring to Seokchangpo includes not only a fraction obtained by precipitating an extract obtained by treating an extraction solvent with an alcohol having 1 to 4 carbon atoms, but also a processed product of a polysaccharide fraction derived from Seokchangpo. For example, the polysaccharide fraction derived from Seokchangpo of the present invention can be manufactured into a powder form by additional processes such as reduced pressure distillation and freeze drying or spray drying.
[0107] In addition, the polysaccharide fraction derived from Aquilegia japonica of the present invention broadly includes a processed Aquilegia japonica polysaccharide product formulated to enable administration of the polysaccharide fraction derived from Aquilegia japonica to animals, for example, a powder obtained by drying the polysaccharide fraction of Aquilegia japonica. Although experiments were conducted with a polysaccharide fraction derived from Aquilegia japonica in the present invention, it would be expected by those skilled in the art that the desired effect can also be achieved in the form of a processed Aquilegia japonica polysaccharide product.
[0108] The extract of Seokchangpo or a fraction thereof of the present invention may be a prebiotic.
[0109] In the present invention, 'using as an active ingredient' or 'comprising as an active ingredient' means including an amount sufficient to achieve the efficacy or activity of the Achyranthes root extract or fraction thereof of the present invention, and specifically, it means including an amount sufficient to enhance immune function or prevent, improve or treat obesity or metabolic disease. For example, the Achyranthes root extract or fraction thereof may be used at a concentration of 10 to 15,000 mg / kg, preferably 100 to 10,000 mg / kg. Since the Achyranthes root extract or fraction thereof is a natural product and does not cause side effects to the human body even when administered in excessive amounts, the quantitative upper and lower limits of the Achyranthes root-derived polysaccharide fraction included in the composition of the present invention may be selected and implemented by those skilled in the art within an appropriate range.
[0110] The term “prevention” in the present invention means anything that suppresses or delays the obesity or metabolic disease.
[0111] The term “improvement” of the present invention means at least reducing the degree of a parameter, for example, a symptom, related to a condition being treated by administration of a composition comprising the extract of Seokchangpo of the present invention or a fraction thereof.
[0112] The food composition of the present invention can be formulated in the same manner as the pharmaceutical composition described below and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meat, chocolate, pizza, ramen, other noodles, gum, ice cream, vitamin complexes, health supplements, and the like.
[0113] The food composition of the present invention may include not only an extract of Aquilegia japonica or a fraction thereof as an effective ingredient, but also ingredients commonly added during food manufacturing, such as proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents. Examples of the carbohydrates mentioned above include monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, oligosaccharides, etc.; and polysaccharides such as dextrin, cyclodextrin, etc., and sugar alcohols such as xylitol, sorbitol, and erythritol. Natural flavoring agents [thaumatin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.]) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is manufactured into a drink or beverage, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be additionally included in addition to the extract of Seokchangpo of the present invention or a fraction thereof.
[0114] The present invention provides a health functional food comprising a food composition containing the above-mentioned Achyranthes root extract or its fraction as an active ingredient for enhancing immune function, or for preventing or improving obesity or metabolic disease. The health functional food refers to a food prepared by adding the Achyranthes root extract or its fraction to food materials such as beverages, teas, spices, gums, and confectionery, or by manufacturing the same in the form of capsules, powders, suspensions, etc., and which, when consumed, brings about a specific health effect. However, unlike general drugs, it has the advantage of not causing side effects that may occur with long-term use of drugs by using food as a raw material. The health functional food of the present invention obtained in this way is very useful because it can be consumed on a daily basis. The amount of the Achyranthes root extract or its fraction added to such a health functional food varies depending on the type of the target health functional food and cannot be uniformly specified. However, it may be added within a range that does not impair the original taste of the food, and is usually in the range of 0.01 to 50 wt%, preferably 0.1 to 20 wt%, based on the target food. Additionally, in the case of health functional foods in the form of pills, granules, tablets, or capsules, the addition may be typically in the range of 0.1 to 100 wt%, preferably 0.5 to 80 wt%. In one specific example, the health functional food of the present invention may be in the form of pills, tablets, capsules, or beverages.
[0115]
[0116] Another aspect of the present invention relates to a prebiotic composition comprising a Seokchangpo extract or a fraction thereof as an active ingredient.
[0117] Since the “Seokchangpo extract or fraction thereof” of the present invention has already been described above, its description is omitted to avoid excessive duplication.
[0118] The composition of the present invention has a prebiotic activity that promotes the increase of beneficial intestinal bacteria over harmful intestinal bacteria by containing an extract of the root of Seokchangpo or a fraction thereof as an active ingredient.
[0119] In addition, the prebiotic composition of the present invention may further include probiotics, and when further including probiotics, it may also be utilized as a synbiotic composition. The added probiotics are not particularly limited as long as they are beneficial bacteria that can improve intestinal health, improve intestinal function, or provide additional functionality. Preferably, at least one of the beneficial intestinal bacteria whose growth and activity are enhanced by the Achyranthes root extract or fractions thereof according to the present invention may be selected.
[0120] The composition comprising the Seokchangpo root extract according to the present invention, particularly the Seokchangpo root hot water extract or a fraction thereof, has remarkably excellent prebiotic activity that improves the intestinal environment by promoting the proliferation and activity of beneficial bacteria present in the intestines and suppressing harmful bacteria when consumed, despite containing less than 2.5% of dietary fiber.
[0121] In other words, it can be seen that the effects of the present invention are obtained through hot water extract of useful components present in the roots of Achyranthes japonica, rather than the dietary fiber of the plant. It can be confirmed that this cannot be obtained from Achyranthes japonica leaves.
[0122] In the present invention, "prebiotics" are substances that, while not hydrolyzed or absorbed in the upper gastrointestinal tract, stimulate the growth or activity of a limited number of specific commensal bacteria, thereby inducing the intestinal flora in a direction beneficial to the host's health. Specifically, they refer to substances that promote the proliferation of beneficial intestinal bacteria over harmful intestinal bacteria, thereby improving intestinal microflora or gut flora.
[0123] The above prebiotic activity can have the effect of improving intestinal health or improving intestinal function by promoting the proliferation of probiotic microorganisms, which are beneficial intestinal microorganisms, and increasing their efficacy.
[0124] In the present invention, "improving intestinal health or improving intestinal function" refers to the action of maintaining a normal intestinal environment by regulating the intestinal flora of beneficial and harmful bacteria. This means that the intestinal flora can be increased and the harmful bacteria flora can be suppressed. Furthermore, it means that the overall function of the intestine can be improved and activated by strengthening the intestinal tight junction barrier function.
[0125] In the present invention, ‘improving intestinal microorganisms’ or ‘improving intestinal flora’ means maintaining the balance between intestinal beneficial bacteria and harmful bacteria by promoting the growth of intestinal beneficial bacteria and inhibiting the growth of intestinal harmful bacteria.
[0126] The composition of the present invention has a prebiotic activity that relatively increases beneficial intestinal bacteria compared to harmful intestinal bacteria, wherein the beneficial intestinal bacteria are at least one selected from the group consisting of Lactobacillus bulgaricus, Lactobalcillus gasseri, Bifidobacterium longum, and Bifidobacterium bifidum, and the harmful intestinal bacteria may be Escherichia coli.
[0127] In the present invention, "intestinal beneficial bacteria" refers to beneficial bacteria existing in the host's intestines and strains that exert a beneficial effect on the intestinal environment upon reaching the intestines after ingestion. These bacteria survive gastric acid and bile acids, reach the small intestine, proliferate and establish there, exhibit beneficial effects within the intestines, and satisfy the conditions of being nontoxic and nonpathogenic. In other words, they can be understood as probiotics.
[0128] The intestinal beneficial bacteria may be at least one selected from the group consisting of strains of the genus Lactobacillus, the genus Lactococcus, the genus Bifidobacterium, and the genus Bacteroides, and are not particularly limited thereto, but preferably at least one selected from the group consisting of Lactobacillus bulgaricus, Lactobalcillus gasseri, Bifidobacterium longum, and Bifidobacterium bifidum, and preferably Lactobacillus bulgaricus MG5167, Lactobalcillus gasseri MG4247, Bifidobacterium longum KCTC3421, and Bifidobacterium It may be Bifidobacterium bifidum ACTC3440.
[0129] According to one embodiment of the present invention, the extract of the root of Seokchangpo has a significantly higher prebiotic activity for all four types of beneficial intestinal bacteria than inulin, a water-soluble dietary fiber, and therefore can be very usefully used when the proliferation effect of the four types of strains among the beneficial intestinal bacteria is required. For example, in cases where the intestinal environment has been disrupted by modern people's eating habits (refined foods, meat-based diet, instant foods) and lifestyle habits (stress and sleeping hours, etc.), especially in cases where the beneficial bacteria such as Lactobacillus bulgaricus, Lactobalcillus gasseri, Bifidobacterium longum, and Bifidobacterium bifidum in the intestinal microflora are low and harmful bacteria are dominant, consuming Achyranthes root extract can improve the intestinal environment to an ideal one where the four strains above are dominant and the growth of harmful bacteria is suppressed.
[0130] Depending on the food material, the useful components and MAC, which is a complex carbohydrate, also differ. Therefore, the MAC that can be consumed varies depending on the type of microorganism. Accordingly, through the experiments described below of the present invention, it was confirmed that the Achyranthes root extract according to the present invention, unlike the 14 types of conventional food extracts, has a heterogeneous and remarkable effect of promoting the production of short-chain fatty acids, which are active in the intestinal microorganisms, when it reaches the large intestine and becomes food for intestinal microorganisms, it is consumed by 4 types of intestinal beneficial microorganisms, thereby increasing the growth and proliferation of intestinal microorganisms.
[0131] As previously discussed, the Achyranthes root extract of the present invention or a fraction thereof acts on the intestinal microbial ecosystem to overcome the imbalance (dysbiosis) in which specific beneficial bacteria undergo changes in their communities or functions due to a strong factor or stress, by promoting growth and significantly inducing the production of short-chain fatty acids, which are metabolites, from beneficial bacteria, thereby allowing the composition and functions to return to their original state, thereby forming an excellent community of beneficial bacteria in the intestines. As the intestinal flora is restored to this stable state, the intestinal environment becomes slightly acidic, thereby preventing the proliferation of not only harmful bacteria but also pathogenic bacteria.
[0132] In addition, in the present invention, 'Seokchangpo' is the root of Seokchangpo, and unlike the extracts of other plants, when it becomes food for intestinal microorganisms, it has remarkably superior growth and proliferation activity for intestinal beneficial bacteria compared to the leaves, stems, flowers, and fruits of Seokchangpo.
[0133] In addition, in the present invention, the 'Seokchangpo root extract' is an extract of the Seokchangpo root using water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof, and the extraction method need not be particularly limited. Preferably, the Seokchangpo root extract may be a Seokchangpo root hot water extract or a Seokchangpo root ethanol aqueous solution, for example, a Seokchangpo root alcohol extract. Most preferably, it may be a Seokchangpo root hot water extract.
[0134] In addition, the above-mentioned Seokchangpo root extract may be obtained by extracting Seokchangpo root with water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
[0135] In addition, the above-mentioned Achyranthes root extract may contain less than 2.5% of dietary fiber, preferably less than 0.1 to 2.5%, and may contain less than 2.0 to 2.5%. It can be confirmed that the above Achyranthes root extract exhibits a more remarkable prebiotic activity than conventional inulin and FOS despite containing a very low content of dietary fiber of less than 2.5% or 2.1%.
[0136] In the production of the above-mentioned Seokchangpo root extract, the Seokchangpo root used may be cut into a certain size, naturally dried in the shade or using a dryer, and then crushed. The drying period is not particularly limited as long as the moisture content of the Seokchangpo root is less than 10-20%.
[0137] In the present invention, the term "extract" includes not only a crude extract obtained by treating an extraction raw material with an extraction solvent, but also a processed product of the crude extract. For example, the extract of the root of Aquilegia japonica can be manufactured into a powder form through additional processes such as reduced pressure distillation and freeze drying or spray drying.
[0138] In addition, the term "extract" in the present invention also includes fractions obtained by further fractionating the crude extract. That is, the extract of the root of Aquilegia japonica includes not only those obtained using an extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, the extract may be purified through various additional methods, such as a polymer fraction obtained by passing it through an ultrafiltration membrane having a certain molecular weight cut-off value, or separation by various chromatographies (designed for separation according to size, charge, hydrophobicity, or affinity).
[0139] In the present invention, "using as an active ingredient" or "comprising as an active ingredient" means including an amount sufficient to achieve the prebiotic activity of the Achyranthes root extract of the present invention, particularly the effect of promoting the proliferation of intestinal beneficial bacteria. Preferably, the composition of the present invention may include Achyranthes root extract or a fraction thereof in an amount of 1 mg / ml or more, preferably 5 mg / ml or more, and more preferably 5 mg / ml to 100 mg / ml.
[0140] The above 'prebiotics composition' contains, in addition to the extract of the root of Aquilegia japonica as an active ingredient, food raw materials that can be used as food as described in the standards and specifications for food commonly used in food manufacturing ('Food Code') and food additives described in the Food Additive Code.
[0141] Although not particularly limited, examples thereof include proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents. The carbohydrates may include monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, lactose, etc.; oligosaccharides or polysaccharides such as dextrin, corn syrup, cyclodextrin, etc.; and sugar alcohols such as xylitol, sorbitol, erythritol, etc. The flavoring agent may include natural flavoring agents [thaumatin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.]) and synthetic flavoring agents (saccharin, aspartame, etc.).
[0142] When preparing a prebiotic composition using the above-mentioned Achyranthes root extract or a fraction thereof as an active ingredient, the Achyranthes root extract or a fraction thereof does not need to be particularly limited as long as it has a content that exhibits prebiotic activity, but may be included in an amount of, for example, 0.1 to 99 wt%, 0.5 to 95 wt%, 1 to 90 wt%, 2 to 80 wt%, 3 to 70 wt%, 4 to 60 wt%, or 5 to 50 wt%.
[0143] In the above prebiotics composition, the effective ingredient, Acorus gramineus root extract or its fraction, may vary depending on the condition, weight, presence or severity of the disease, and duration of the ingestion, but may be appropriately selected by a person skilled in the art. For example, based on the daily dosage, it may be 1 to 5,000 mg, preferably 5 to 2,000 mg, more preferably 10 to 1,000 mg, still more preferably 20 to 800 mg, and most preferably 50 to 500 mg. The number of administrations need not be particularly limited, but may be adjusted by a person skilled in the art within the range of 3 times a day to once a week. In the case of long-term intake for the purpose of health and hygiene or health control, the amount may be below the above range.
[0144] The above prebiotic composition does not need to be particularly limited, but may be, for example, in the form of powder, granules, tablets, capsules, pills, extracts, jelly formulations, tea bags, or beverage formulations.
[0145] In addition, the above-mentioned Aconite root extract or its fraction can be added to general foods to improve intestinal flora through prebiotic activity, and the foods to which it can be added are not particularly limited, but for example, it can be added to confectionery, bread or rice cakes, cocoa products or chocolates, meat or egg products, fish products, tofu or jelly products, noodles, teas, coffee, beverages, special-purpose foods, soy sauce, seasoned foods, dressings, kimchi, salted seafood, pickled foods, stewed foods, alcoholic beverages, dried foods, and other foods listed in the standards and ingredient specifications for livestock products ('Livestock Products Code') pursuant to Article 7 of the Food Sanitation Act. In addition, it can be added to dairy products, processed meat products, packaged meat products, and processed egg products listed in the processing standards and ingredient specifications for livestock products pursuant to Article 4 of the Livestock Products Sanitation Management Act.
[0146] Meanwhile, a composition containing the above-mentioned Seokchangpo root extract or a fraction thereof as an active ingredient can be used alone as a “prebiotic health functional food”, and can be used as a “health functional food that helps improve intestinal flora”, a “health functional food that helps improve intestinal environment”, or a “health functional food that helps improve intestinal health or intestinal function”.
[0147] The above "health functional food" refers to a food manufactured (including processed) in accordance with legal standards using raw materials or ingredients with beneficial functions for the human body (Article 3, Paragraph 1 of the Health Functional Food Act). While the terminology and scope of the above "health functional food" may vary by country, it can be defined as a "dietary supplement" in the United States, a "food supplement" in Europe, a "health functional food" or "food for special health use (FoSHU)" in Japan, or a "health food" in China.
[0148] The above food composition or health functional food may additionally contain food additives, and its suitability as a food additive shall be determined in accordance with the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the ‘Food Additives Code’, unless otherwise provided.
[0149] In addition, the above health functional food may be used in combination with the above-mentioned Seokchangpo root extract or its fraction and a health functional food material related to prebiotic activity.
[0150]
[0151] Another aspect of the present invention relates to a food composition for preventing or improving leaky gut syndrome, comprising an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0152] Since the “Seokchangpo extract or fraction thereof” and “food composition” of the present invention have already been described above, their description is omitted to avoid excessive duplication.
[0153] The human intestinal tract, a reservoir of intestinal bacteria, comprises a series of defense mechanisms, including a mucosal barrier, immunoglobulin secretion, and the macrophage system. The intestinal mucosa acts as a protective barrier, blocking various intestinal bacteria and toxins from entering the bloodstream. It is tightly bound to the epithelial cell layer. In other words, the intestinal mucosa has a dual function: it blocks foreign substances while also allowing them to pass through and be absorbed.
[0154] The intestinal mucosal cells maintain a certain gap between cells, but when a stimulus or damage is applied during the digestion and absorption process, the intestinal mucosal permeability increases, allowing macromolecules to pass back and forth between the cells. At this time, the barrier function is not properly performed, resulting in macromolecules in the blood leaking into the intestinal lumen or macromolecules in the lumen entering directly into the blood. This is called a "leaky gut" condition. The symptoms that appear at this time are collectively called leaky gut syndrome (LGS), and appear in various clinical conditions such as aging, allergies, multiple trauma, rheumatoid arthritis, inflammatory bowel disease, chronic fatigue syndrome, and irritable bowel syndrome. In addition, due to increased intestinal mucosal permeability or damage to the intestinal mucosa, pathogens, antigens, and putrefactive substances enter the intestinal mucosa, causing an inflammatory response, and endotoxins enter the bloodstream, causing bacterial translocation and intestinal endotoxemia, resulting in various inflammatory and immune responses.
[0155] Leaky gut syndrome can be caused by a variety of factors, but it's known to be particularly triggered by a high-fat diet. With the recent surge in high-protein, high-fat diets, particularly meat-based diets, replacing plant-based diets, and the increasing number of people consuming high-fat foods instead of carbohydrates for dieting, the risk of leaky gut syndrome is also rapidly increasing. Therefore, the search for new substances to address this issue is absolutely essential.
[0156] The composition of the present invention has a purpose of improving or preventing the above-mentioned leaky gut syndrome, and can also be said to be a composition having the effect of improving, preventing, alleviating, suppressing, and treating increased intestinal permeability due to various causes. This has the effect of improving, preventing, and treating leaky gut syndrome, which causes various diseases due to increased intestinal permeability, such as leakage of high molecular substances in the blood into the intestinal lumen or direct entry of high molecular substances within the lumen into the blood. Prevention or treatment of leaky gut syndrome may mean suppressing the phenomenon of increased intestinal mucosal permeability, which causes the gaps between intestinal mucosal cells to become loose and allow high molecular substances to pass back and forth.
[0157] In addition, the composition has the effect of improving the intestinal environment, restoring beneficial intestinal microorganisms, reducing intestinal mucosal permeability, restoring intestinal length, and strengthening intestinal tight junction proteins.
[0158] According to one embodiment of the present invention, it may have a purpose of improving, preventing or treating gut leaky gut syndrome caused by a high-fat diet. Specifically, when the extract of the root of Aquilegia japonica according to the present invention is administered, the intestinal environment destroyed by a high-fat diet is improved, intestinal beneficial microorganisms are restored, intestinal permeability increased by a high-fat diet is reduced, and intestinal length reduced by a high-fat diet is restored.
[0159] The above 'food composition' includes, in addition to the extract of the root of Seokchangpo or a fraction thereof as an active ingredient, food raw materials that can be used as food as described in the standards and specifications for food commonly used in food manufacturing ('Food Code') and food additives described in the Food Additive Code.
[0160] Although not particularly limited, examples thereof include proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents. The carbohydrates may include monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, lactose, etc.; oligosaccharides or polysaccharides such as dextrin, corn syrup, cyclodextrin, etc.; and sugar alcohols such as xylitol, sorbitol, erythritol, etc. The flavoring agent may include natural flavoring agents [thaumatin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.]) and synthetic flavoring agents (saccharin, aspartame, etc.).
[0161] When manufacturing a food composition using the above-mentioned Achyranthes root extract or a fraction thereof as an active ingredient, the Achyranthes root extract or a fraction thereof does not need to be particularly limited as long as it has an effect of preventing or improving leaky gut syndrome, but may be included in an amount of, for example, 0.1 to 99 wt%, 0.5 to 95 wt%, 1 to 90 wt%, 2 to 80 wt%, 3 to 70 wt%, 4 to 60 wt%, or 5 to 50 wt%.
[0162] In the above food composition, the effective ingredient, Acorus gramineus root extract or its fraction, may vary depending on the condition, weight, presence or severity of the disease, and duration of the ingestion, but may be appropriately selected by a person skilled in the art. For example, the daily dosage may be 1 to 5,000 mg, preferably 5 to 2,000 mg, more preferably 10 to 1,000 mg, still more preferably 20 to 800 mg, and most preferably 50 to 500 mg. The number of administrations need not be particularly limited, but may be adjusted by a person skilled in the art within the range of 3 times a day to once a week. In the case of long-term intake for the purpose of health and hygiene or health control, the dosage may be below the above range.
[0163] The above food composition need not be particularly limited, but may be, for example, a powder, granule, tablet, capsule, pill, extract, jelly formulation, tea bag formulation, or beverage formulation.
[0164] In addition, the above-mentioned Seokchangpo root extract or its fraction can be added to general foods to prevent or improve leaky gut syndrome, and the foods to which it can be added are not particularly limited, but for example, it can be added to confectionery, bread or rice cakes, cocoa products or chocolates, meat or egg products, fish products, tofu or jelly products, noodles, teas, coffee, beverages, special-purpose foods, soy sauce, seasoned foods, dressings, kimchi, salted seafood, pickled foods, stewed foods, alcoholic beverages, dried foods, and other foods exemplified in the standards and ingredient specifications for livestock products ('Livestock Products Code') pursuant to Article 7 of the Food Sanitation Act. In addition, it can be added to dairy products, processed meat products, packaged meat products, and processed egg products exemplified in the processing standards and ingredient specifications for livestock products pursuant to Article 4 of the Livestock Products Sanitation Management Act.
[0165] Meanwhile, a food composition containing the above-mentioned Seokchangpo root extract or a fraction thereof as an active ingredient can be used alone as a “health functional food that helps prevent or improve leaky gut syndrome,” and can be used as a “health functional food that helps reduce intestinal mucosal permeability,” or a “health functional food that helps intestinal mucosal permeability.”
[0166] The above "health functional food" refers to a food manufactured (including processed) in accordance with legal standards using raw materials or ingredients with beneficial functions for the human body (Article 3, Paragraph 1 of the Health Functional Food Act). While the terminology and scope of the above "health functional food" may vary by country, it can be defined as a "dietary supplement" in the United States, a "food supplement" in Europe, a "health functional food" or "food for special health use (FoSHU)" in Japan, or a "health food" in China.
[0167] The above food composition or health functional food may additionally contain food additives, and its suitability as a food additive shall be determined in accordance with the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the ‘Food Additives Code’, unless otherwise provided.
[0168] In addition, the above health functional food may be used in combination with the above-mentioned Seokchangpo root extract or its fraction and a health functional food material related to the prevention or improvement of leaky gut syndrome.
[0169]
[0170] Another aspect of the present invention relates to a pharmaceutical composition for preventing or treating a disease caused by a weakened immune system, comprising an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0171] Since the “Seokchangpo extract or fraction thereof” and “enhancement of immune function” of the present invention have already been described above, their description is omitted to avoid excessive duplication.
[0172] The diseases caused by the aforementioned weakened immune system may include, but are not limited to, cancer, infectious diseases, inflammatory diseases, allergic diseases, colds, and chronic fatigue. Furthermore, even if not specifically affected by these diseases, the composition of the present invention can reduce the risk of infection and development of various bacterial and viral diseases by enhancing the body's overall immune function.
[0173] As used herein, the term "containing as an active ingredient" means including a sufficient amount to achieve the efficacy or activity of the polysaccharide fraction derived from the root of Achyranthes chinensis. For example, the Achyranthes chinensis extract or its fraction is used at a concentration of 10 to 1500 μg / ml, preferably 10 to 100 μg / ml. Since the polysaccharide fraction derived from the root of Achyranthes chinensis is a natural product and does not cause side effects to the human body even when administered in excessive amounts, the quantitative upper limit of the polysaccharide fraction derived from the root of Achyranthes chinensis contained in the composition of the present invention can be selected and implemented by those skilled in the art within an appropriate range.
[0174] The pharmaceutical composition of the present invention can be prepared using pharmaceutically suitable and physiologically acceptable auxiliary agents in addition to the above-mentioned effective ingredient, and the auxiliary agents can include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, glidants, or flavoring agents.
[0175] The above pharmaceutical composition may be preferably formulated as a pharmaceutical composition by additionally including one or more pharmaceutically acceptable carriers in addition to the above-described effective ingredients for administration.
[0176] The pharmaceutical composition may be in the form of granules, powders, tablets, topical preparations for skin, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops, or injectable solutions. For example, for formulation in the form of tablets or capsules (oral preparations), the active ingredient may be combined with an orally acceptable, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, etc. In addition, if desired or necessary, suitable binders, lubricants, disintegrants, and coloring agents may also be included in the mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose, or beta-lactose, natural and synthetic gums such as corn sweetener, acacia, tracheacanth, or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, etc.
[0177] In the composition to be formulated as a liquid solution, acceptable pharmaceutical carriers include those that are sterile and biocompatible, such as saline solution, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures of one or more of these components. If necessary, other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into injectable formulations such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets.
[0178] Furthermore, it can be preferably formulated according to each disease or ingredient using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, as an appropriate method in the relevant field.
[0179] The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., and oral administration is preferred.
[0180] The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, patient age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity. A skilled physician can easily determine and prescribe a dosage effective for the desired treatment or prevention. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g / kg.
[0181] The pharmaceutical composition of the present invention may be prepared in unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient, or may be prepared by placing it in a multi-dose container. In this case, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granule, tablet, or capsule, and may additionally include a dispersing agent or stabilizer.
[0182]
[0183] The present invention also provides a use of a Seokchangpo extract or a fraction thereof for the manufacture of a medicine or food for enhancing human immune function. As described above, a Seokchangpo extract or a fraction thereof can be used for enhancing immune function.
[0184] In addition, the present invention provides a method for enhancing immune function comprising administering an effective amount of a Ginkgo biloba extract or a fraction thereof to a mammal.
[0185] The term "mammal" as used herein refers to a mammal that is the subject of treatment, observation or experimentation, preferably a human.
[0186] The term "effective amount" as used herein means the amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue, animal, or human, as conceived by a researcher, veterinarian, physician, or other clinician, including an amount that induces alleviation of the symptoms of the disease or disorder. The effective amount and frequency of administration of the active ingredient of the present invention may vary depending on the desired effect. Therefore, the optimal dosage to be administered can be readily determined by those skilled in the art, and may be adjusted according to various factors including the type of disease, the severity of the disease, the content of the active ingredient and other ingredients contained in the composition, the type of formulation, and the patient's age, weight, general health, sex, and diet, the time of administration, the route of administration, and the excretion rate of the composition, the treatment period, and concurrently used drugs. In the method for preventing, treating, or improving a disease of the present invention, in the case of adults, it is preferable to administer the Achyranthes japonica extract or its fractions once or several times a day at a dosage of 0.001 g / kg to 10 g / kg.
[0187] In the treatment method of the present invention, a composition containing a Seokchangpo extract or a fraction thereof as an active ingredient can be administered in a conventional manner via oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular, or intradermal routes.
[0188]
[0189] Another aspect of the present invention relates to a pharmaceutical composition for preventing or treating obesity or metabolic disease, comprising an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0190] Since the “Seokchangpo extract or fraction thereof” and “obesity or metabolic disease” of the present invention have already been described above, their description is omitted to avoid excessive duplication.
[0191] In this specification, 'treatment' means reversing, alleviating, inhibiting the progression of, or preventing the symptoms of obesity or metabolic disease.
[0192] The pharmaceutical composition of the present invention can be manufactured using pharmaceutically suitable and physiologically acceptable excipients in addition to the effective ingredient, the extract of Seokchangpo or a fraction thereof, and the excipients can include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, glidants, or flavoring agents.
[0193] The above pharmaceutical composition may be preferably formulated as a pharmaceutical composition by additionally including one or more pharmaceutically acceptable carriers in addition to the above-described effective ingredients for administration.
[0194] The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., and oral administration is preferred.
[0195] The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity, and a generally skilled physician can easily determine and prescribe an effective dosage for the desired treatment or prevention. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.0001-10 g / kg, and more preferably, it may be administered at a dosage of 0.001 g / kg to 10 g / kg.
[0196] The pharmaceutical composition of the present invention may be prepared in unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient, or may be prepared by placing it in a multi-dose container. In this case, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granule, tablet, or capsule, and may additionally include a dispersing agent or stabilizer.
[0197]
[0198] The present invention also provides the use of a Seokchangpo extract or a fraction thereof for the manufacture of a medicine or food for the prevention, improvement, or treatment of obesity or metabolic diseases. As described above, a Seokchangpo extract or a fraction thereof can be used for the prevention, improvement, or treatment of obesity or metabolic diseases.
[0199]
[0200] In addition, the present invention provides a method for preventing, improving or treating obesity or metabolic disease, comprising administering an effective amount of a Seokchangpo extract or a fraction thereof to a mammal.
[0201] The term "mammal" as used herein refers to a mammal that is the subject of treatment, observation or experimentation, preferably a human.
[0202] The term "effective amount" as used herein means that amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue, animal, or human, as contemplated by a researcher, veterinarian, physician, or other clinician, including an amount that induces alleviation of the symptom in question. The effective amount and frequency of administration of the active ingredient of the present invention may vary depending on the desired effect. Therefore, the optimal dosage to be administered can be readily determined by one skilled in the art, and may be adjusted according to various factors, including the degree of obesity, body weight, body fat, serum triglyceride and endotoxin concentrations, the content of the active ingredient and other ingredients contained in the composition, the type of formulation, and the patient's age, body weight, general health, sex, and diet, administration time, administration route, treatment period, and concurrently used drugs. In the method for prevention, treatment or improvement of the present invention, in the case of adults, it is preferable to administer the extract of Seokchangpo or a fraction thereof once or several times a day at a dosage of 0.0001 g / kg to 10 g / kg, and more preferably, it may be administered at a dosage of 0.001 g / kg to 10 g / kg.
[0203] In the treatment method of the present invention, a composition containing an extract of Aquilegia japonica or a fraction thereof as an active ingredient can be administered in a conventional manner via oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular or intradermal routes, and preferably can be administered orally.
[0204]
[0205] Another aspect of the present invention relates to a pharmaceutical composition for preventing or treating leaky gut syndrome, comprising an extract of Seokchangpo or a fraction thereof as an active ingredient.
[0206] Since the “Seokchangpo extract or fraction thereof”, “leakage syndrome”, and “pharmaceutical composition” of the present invention have already been described above, their descriptions are omitted to avoid excessive duplication.
[0207] According to one embodiment of the present invention, it may have a use for improving, preventing or treating gut leaky gut syndrome caused by a high-fat diet, and specifically, when the extract of the root of Aquilegia japonica or a fraction thereof according to the present invention is administered, the intestinal environment destroyed by a high-fat diet is improved, intestinal beneficial microorganisms are restored, intestinal permeability increased by a high-fat diet is reduced, and intestinal length reduced by a high-fat diet is restored.
[0208] The composition of the present invention is a pharmaceutical composition, and can be prepared using, in addition to the effective ingredient, the extract of the root of Aquilegia japonica or a fraction thereof, a pharmaceutically suitable and physiologically acceptable excipient, and the excipient may be an excipient, a disintegrant, a sweetener, a binder, a coating agent, a swelling agent, a lubricant, a glidant, or a flavoring agent.
[0209] The above pharmaceutical composition may be preferably formulated as a pharmaceutical composition by additionally including one or more pharmaceutically acceptable carriers in addition to the above-described effective ingredients for administration.
[0210] The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., and oral administration is preferred.
[0211] The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity, and a generally skilled physician can easily determine and prescribe an effective dosage for the desired treatment or prevention. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention may be 0.001 to 10 g / kg, preferably 0.01 to 10 g / kg, and more preferably 0.1 to 10 g / kg.
[0212]
[0213] In addition, the present invention provides a method for improving, preventing, or treating leaky gut syndrome, comprising administering to a mammal an effective amount of a root extract of Atractylodes japonica or a fraction thereof.
[0214] Since the “Seokchangpo extract or fraction thereof” and “leakage of intestine syndrome” of the present invention have already been described above, their description is omitted to avoid excessive duplication.
[0215] The term "mammal" as used herein refers to a mammal that is the subject of treatment, observation or experimentation, preferably a human.
[0216] The term "effective amount" as used herein means the amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue, animal, or human, as conceived by a researcher, veterinarian, physician, or other clinician, including an amount that induces alleviation of the symptom in question. The effective amount and frequency of administration of the active ingredient of the present invention may vary depending on the desired effect. Therefore, the optimal dosage to be administered can be readily determined by one skilled in the art, and may be adjusted according to various factors, including the degree of intestinal health or degree of intestinal leakiness, the content of the active ingredient and other ingredients contained in the composition, the type of formulation, and the patient's age, weight, general health, sex, and diet, the time of administration, the route of administration, and the excretion rate of the composition, the treatment period, and concurrently used drugs. In the method for prevention, treatment, or improvement of the present invention, in the case of adults, it is preferable to administer the Achyranthes root extract or its fractions at a dose of 0.001 g / kg to 10 g / kg, preferably 0.1 to 10 g / kg, once or several times a day.
[0217] In the treatment method of the present invention, a composition comprising a root extract of Aquilegia japonica or a fraction thereof as an active ingredient can be administered in a conventional manner via oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular or intradermal routes, and preferably oral administration.
[0218]
[0219] Hereinafter, the present invention will be described in detail by examples, but the present invention is not limited to the following examples.
[0220]
[0221] <Example>
[0222] Example 1: Polysaccharide fraction from the root of Seokchangpo (SFRP)
[0223] The roots of Seokchangpo were purchased from Dangjin, South Chungcheong Province, Korea. The roots were dried in a drying oven at 50°C and then ground to a particle size of 2.0 mm or less using a grinder to prepare Seokchangpo powder.
[0224] 20 times (w / v) of distilled water was added to 5 g of the above Seokchangpo powder, and reflux extraction was performed at 80°C for 3 hours to obtain a hot water extract. The hot water extract was centrifuged at 4°C and 6,000×g for 20 minutes, the residue was removed, and the supernatant was separated. The supernatant was concentrated under reduced pressure using a rotary vacuum evaporator, and 80% ethanol was added to the supernatant of the concentrated hot water extract under reduced pressure to a final concentration of 80%, and the polysaccharide was precipitated by standing at 10°C for 72 hours, and the precipitate was freeze-dried to obtain a Seokchangpo root-derived polysaccharide fraction (SFRP).
[0225]
[0226] Example 2: Sophora japonica root hot water extract (SFRE)
[0227] We purchased Aster root produced in Dangjin, South Chungcheong Province, South Korea. The prepared Aster root was washed with clean water, dried, and then dried in a drying oven at 50°C to a moisture content of less than 10–20%. The dried Aster root was then ground to a particle size of 2.0 mm or less using a grinder to prepare Aster powder.
[0228] Distilled water was mixed with the above-mentioned Seokchangpo powder at a weight ratio of 1:20 and first reflux extraction was performed at a temperature of 80℃ for 3 hours. The extract was filtered and centrifuged to recover the supernatant. The recovered supernatant was concentrated under reduced pressure using a rotary vacuum evaporator. The concentrated Seokchangpo root hot water extract was freeze-dried for 72 hours to produce Seokchangpo root hot water extract powder (yield compared to dried sample: 30%) (SFRE, sweet flag root extract). The Seokchangpo root hot water extract powder was stored at -20℃ and used as an experimental sample.
[0229]
[0230] <Example of an exam>
[0231] All experiments were repeated three times, and statistical analysis was performed using SPSS Ver. 20.0 (SPSS Inc. Chicago, USA). The results of the experiments were expressed as the mean and standard deviation of the mean. The characteristics of the treatment groups were tested for significance (p<0.05) using Tukey's post-hoc test and ANOVA (Analysis of variance).
[0232]
[0233] <Immune function enhancement activity>
[0234] Example 1: Polysaccharide fraction from the root of Seokchangpo (SFRP)
[0235] The roots of Seokchangpo were purchased from Dangjin, South Chungcheong Province, Korea. The roots were dried in a drying oven at 50°C and then ground to a particle size of 2.0 mm or less using a grinder to prepare Seokchangpo powder.
[0236] 20 times (w / v) of distilled water was added to 5 g of the above Seokchangpo powder, and reflux extraction was performed at 80°C for 3 hours to obtain a hot water extract. The hot water extract was centrifuged at 4°C and 6,000×g for 20 minutes, the residue was removed, and the supernatant was separated. The supernatant was concentrated under reduced pressure using a rotary vacuum evaporator, and 80% ethanol was added to the supernatant of the concentrated hot water extract under reduced pressure to a final concentration of 80%, and the polysaccharide was precipitated by standing at 10°C for 72 hours, and the precipitate was freeze-dried to obtain a Seokchangpo root-derived polysaccharide fraction (SFRP).
[0237]
[0238] Example 2: Sophora japonica root hot water extract (SFRE)
[0239] We purchased Aster root produced in Dangjin, South Chungcheong Province, South Korea. The prepared Aster root was washed with clean water, dried, and then dried in a drying oven at 50°C to a moisture content of less than 10–20%. The dried Aster root was then ground to a particle size of 2.0 mm or less using a grinder to prepare Aster powder.
[0240] Distilled water was mixed with the above-mentioned Seokchangpo powder at a weight ratio of 1:20 and first reflux extraction was performed at a temperature of 80℃ for 3 hours. The extract was filtered and centrifuged to recover the supernatant. The recovered supernatant was concentrated under reduced pressure using a rotary vacuum evaporator. The concentrated Seokchangpo root hot water extract was freeze-dried for 72 hours to produce Seokchangpo root hot water extract powder (yield compared to dried sample: 30%) (SFRE, sweet flag root extract). The Seokchangpo root hot water extract powder was stored at -20℃ and used as an experimental sample.
[0241]
[0242] <Example of an exam>
[0243] All experiments were repeated three times, and statistical analysis was performed using SPSS Ver. 20.0 (SPSS Inc. Chicago, USA). The results of the experiments were expressed as the mean and standard deviation of the mean. The characteristics of the treatment groups were tested for significance (p<0.05) using Tukey's post-hoc test and ANOVA (Analysis of variance).
[0244] Test Example 1-1: Composition Analysis of Fractions
[0245] Total sugar content was measured by the phenol-sulfuric acid method using glucose as a standard; uronic acid and protein contents were measured by the mhydroxydiphenyl sulfate method using galacturonic acid as a standard and the Bradford method using bovine serum albumin (BSA, SigmaAldrich, St. Louis, MO, USA), respectively.
[0246] The monosaccharide composition was determined by high performance anion exchange chromatography coupled with pulsed amperometric chromatography (HPAEC-PAD).
[0247] In Table 1 below, Uronic acid refers to Galacturonic acid and Glucuronic acid. The sugars that make up neutral sugars are indicated by their content (weight %) based on the total neutral sugar.
[0248] Chemical composition (unit: wt%) Example 1 (SFRP) Example 2 (SFRE) Neutral sugar 30.6±0.5 27.23±4.21 Uronic acid 5.3±0.3 1.89±0.35 Polyphenol 2.3±0.5 2.70±0.31 Flavonoid 3.2±0.1 1.03±0.24 Carbohydrate 68.8±0.4 7 1.42±0.73 Protein 0.0±0.01 7.82±0.48 Component of neutral sugar (unit: Weight%)arabinose9.2±0.33.55±0.24galactose9.2±0.23.24±0.35rhamnose1.3±0.10.61±0.0 7xylose5.4±0.11.54±0.08glucose5.5±0.218.24±2.33fucose0.1±0.00.05±0.00Component of Uronic acid (unit: weight%)Galacturonic acid4.6±0.11.54±0.09Glucuronic acid0.8±0.00.35±0.01
[0249] As shown in Table 1 above, it was confirmed that the polysaccharide fraction derived from the root of Atractylodes japonica prepared according to Example 1 of the present invention had a higher content of neutral sugar, acidic sugar, and carbohydrate than the hot water extract of the root of Atractylodes japonica of Example 2.
[0250] In particular, among the neutral sugars, it was confirmed that the polysaccharide fraction derived from the root of Atractylodes japonica prepared according to Example 1 had a higher content of arabinose, rhamnose, galactose, xylose, and fucose than the hot water extract of the root of Atractylodes japonica prepared according to Example 2.
[0251] In addition, among the acidic sugars, it was confirmed that the content of galacturonic acid and glucuronic acid in the polysaccharide fraction derived from the root of Atractylodes japonica prepared according to Example 1 was higher than that in the hot water extract of the root of Atractylodes japonica prepared according to Example 2.
[0252]
[0253] Test Example 2: Measurement of RAW 264.7 macrophage viability
[0254] RAW 264.7 cells, a mouse macrophage cell line, were obtained from the American Type Culture Collection (ATCC). 3X10 of the RAW 264.7 cells were seeded in a 96-well plate. 4 Cells were seeded at 10 cells / well and cultured for 24 hours under conditions of 37°C and 5% CO2. Afterwards, the control group was not treated with anything, the positive control group was treated with 1 μg / mL of lipopolysaccharide (LPS; Sigma-Aldrich), and the polysaccharide fraction derived from the root of Acorus coccinea of Example 1 and the hot water extract of the root of Acorus coccinea of Example 2 were treated at concentrations of 0.1, 0.5, 1, 5, 10, and 20 μg / mL, respectively, and cultured for 24 hours. Afterwards, 10 μL of cell counting kit-8 (CCK-8; Dojindo Laboratories Co., Ltd.) reagent was added, and the absorbance was measured at 450 nm after 3 hours.
[0255] Figure 1 is a graph measuring cell viability for a polysaccharide fraction derived from the root of Seokchangpo prepared according to Example 1 of the present invention and a hot water extract of Seokchangpo root prepared according to Example 2.
[0256] As shown in Fig. 1, it was confirmed that the polysaccharide fraction derived from the root of Atractylodes japonica prepared according to Example 1 and the hot water extract of the root of Atractylodes japonica prepared according to Example 2 exhibited cell viability rates of 95% or more at all concentrations. This means that all samples were not toxic to RAW 264.7 cells.
[0257]
[0258] Test Example 3: Measurement of nitric oxide (NO) and cytokine production by RAW 264.7 cell stimulation.
[0259] Macrophages are distributed in almost all tissues of the body and play a role in phagocytosing and removing foreign substances and waste. During this process, macrophages secrete various cytokines and nitric oxide (NO) to regulate the immune response. In other words, activated macrophages are known to induce subsequent immune responses by producing cytokines such as TNF-α, IL-6, and IL-1β, which are considered important factors in the innate immune response. They also exhibit various functions such as promoting the synthesis of immunoglobulins as a B cell stimulator that induces the terminal differentiation of plasma cells, which are antibody-producing cells of B cells. Nitric oxide (NO) is also an important signaling substance that plays a defensive role against tumor cells and intracellularly infected microorganisms in the immune system. In the present invention, the degree of activation of the immune response was confirmed by measuring the secretion of NO, TNF-α, IL-1β, and IL-6 when macrophages were treated with the samples of Examples 1 and 2 at different concentrations (0.5, 1, 5, 10, 20 μg / mL).
[0260]
[0261] 3-1: Measurement of nitric oxide (NO) production capacity
[0262] When macrophages are activated, they secrete cytokines such as nitric oxide (NO) and tumor necrosis factor-α (TNF-α). NO production is known to be an important signaling molecule in the immune system that plays a defensive role against tumor cells and intracellularly infected microorganisms. While excessive NO production can induce systemic inflammation, negatively impacting the body, adequate NO production is considered a crucial factor in innate immunity.
[0263] To confirm the immune-enhancing ability, the concentration of NO2- produced in the cell culture medium was measured using Griess reagent [1% (w / v) sulfanilamide in 5% (v / v) phosphoric acid]. That is, 100 μL of the cell culture supernatant after the culture was completed was treated with the same amount of Griess reagent (Sigma-Aldrich), and the reaction was carried out at room temperature for 15 minutes, after which the absorbance was measured at 540 nm. At this time, the nitric oxide (NO) concentration was calculated from a standard curve created using sodium nitrite and converted.
[0264] At this time, lipopolysaccharide (LPS) was used as a positive control at 1 μg / mL, and DMEM medium was treated as an untreated control and additionally cultured for 24 hours. The supernatant of the cell culture solution after culture was completed was mixed with an equal amount of Griess reagent, and the reaction was performed at room temperature for 15 minutes. The absorbance was measured at 540 nm, and the nitric oxide (NO) concentration was calculated from a standard curve created using sodium nitrite and converted.
[0265] The results of measuring the amount of nitric oxide (NO) produced when samples Example 1 (SFRP) and Example 2 (SFRE) were treated at different concentrations together with a positive control group treated only with lipopolysaccharide (LPS, 1 μg / mL) are as shown in Figure 2.
[0266] FIG. 2 is a graph showing the amount of nitric oxide (NO) measured for a polysaccharide fraction derived from the root of Seokchangpo prepared according to Example 1 of the present invention and a hot water extract of Seokchangpo root prepared according to Example 2.
[0267] As shown in Fig. 2, it was confirmed that the polysaccharide fraction derived from the roots of Aquilegia japonica prepared according to Example 1 significantly promoted the NO secretion ability of macrophages in a concentration-dependent manner, and in particular, a significant increase was observed at a concentration of 10 to 20 μg / mL.
[0268] On the other hand, it was confirmed that the hot water extract of the root of Seokchangpo prepared according to Example 2 improved the NO secretion ability of macrophages in a concentration-dependent manner at a concentration of 5 to 20 μg / mL, but was lower than that of Example 1.
[0269]
[0270] 3-2: Measurement of cytokine production
[0271] Activated macrophages are known to induce subsequent immune responses by producing cytokines such as TNF-α, IL-β, and IL-6, which are considered important factors in the innate immune response, and they exhibit various functions such as promoting the synthesis of immunoglobulins as a B cell stimulator that induces terminal differentiation of plasma cells, which are antibody-producing cells of B cells.
[0272] The degree of immune response activation was confirmed by measuring the secretion of TNF-α, IL-β, and IL-6 when macrophages were treated with the samples of Examples 1 and 2 at different concentrations (0.5, 1, 5, 10, 20 μg / mL).
[0273] The production of TNF-α, IL-1β, and IL-6 by macrophages was analyzed by the enzyme-linked immunosorbent assay (ELISA) method. RAW264.7 cells were seeded in a 96-well plate at a density of 3X10 4 Cells were dispensed at a concentration of 10 cells / mL and cultured for 24 hours under conditions of 37°C and 5% CO2. Afterwards, the polysaccharide fraction derived from the roots of Achyranthes root of Example 1 and the hot water extract of Achyranthes root of Example 2 were treated at concentrations of 0.5, 1, 5, 10, and 20 μg / mL or LPS 1 μg / mL, and cultured for 24 hours. Only the culture supernatant was recovered and the amount of each cytokine produced was measured using an ELISA kit (Abcam).
[0274] FIG. 3 is a graph measuring the TNF-α production ability of a polysaccharide fraction derived from Aquilegia japonica root prepared according to Example 1 of the present invention and a hot water extract of Aquilegia japonica root prepared according to Example 2; FIG. 4 is a graph measuring the IL-1β level of a polysaccharide fraction derived from Aquilegia japonica root prepared according to Example 1 of the present invention and a hot water extract of Aquilegia japonica root prepared according to Example 2; FIG. 5 is a graph measuring the IL-6 level of a polysaccharide fraction derived from Aquilegia japonica root prepared according to Example 1 of the present invention and a hot water extract of Aquilegia japonica root prepared according to Example 2.
[0275] As shown in FIGS. 3 to 5, it was confirmed that the polysaccharide fraction derived from the roots of Atractylodes japonica prepared according to Example 1 increased the production ability of TNF-α, IL-1β, and IL-6 in a concentration-dependent manner.
[0276] In particular, the production ability of TNF-α was the best at concentrations of 10 and 20 μg / mL of the polysaccharide fraction derived from the root of Achyranthes japonica prepared according to Example 1, the production ability of IL-1β was also the best at concentrations of 10 and 20 μg / mL of the polysaccharide fraction derived from the root of Achyranthes japonica prepared according to Example 1, and the production ability of IL-6 was also the best at concentrations of 10 and 20 μg / mL of the polysaccharide fraction derived from the root of Achyranthes japonica prepared according to Example 1.
[0277] On the other hand, it was confirmed that the hot water extract of the root of Seokchangpo prepared according to Example 2 had significantly lower production abilities of TNF-α, IL-1β, and IL-6 compared to Example 1.
[0278] These results indicate that the polysaccharide fraction derived from the root of Atractylodes japonica (Example 1) exhibits superior immune-enhancing efficacy by stimulating immune cells and increasing immune activity more than the hot water extract of Atractylodes japonica (Example 2).
[0279]
[0280] <Prevention, improvement, or treatment of obesity or metabolic disease>
[0281] Example 3: Polysaccharide fraction (SFP) from the root of Seokchangpo
[0282] The roots of Seokchangpo were purchased from Dangjin, South Chungcheong Province, Korea. The roots were dried in a drying oven at 50°C and then ground to a particle size of 2.0 mm or less using a grinder to prepare Seokchangpo powder.
[0283] 5 g of Seokchangpo powder was added with distilled water equivalent to 20 times the volume, and refluxed at 80°C for 3 hours to obtain a hot water extract. After filtering the hot water extract, it was concentrated under reduced pressure to 1 / 10 of the extract using a rotary vacuum evaporator, and 75% (v / v) ethanol equivalent to 4 times the volume was added to the hot water extract concentrated under reduced pressure, and precipitated for 48 hours. This was centrifuged (6000 rpm, 635×g, 30 min) to obtain a precipitate, and a small amount of distilled water was added to re-dissolve the precipitate. Dialysis was performed for 48 hours using a dialysis membrane with a molecular weight cutoff of 12 kDa (MW cut off 12,000, Sigma-Aldrich Co., St. Louis, MO, USA) to remove low-molecular-weight substances, and lyophilized for 72 hours to obtain a sweet flag root polysaccharide fraction (SFP) derived from Aquilegia japonica.
[0284]
[0285] Test Example 1-2: Component Analysis of Fractions
[0286] 1-2-1: General component analysis
[0287] The general component contents (mg / g) contained in the polysaccharide fraction derived from Seokchangpo according to Example 3 were analyzed and shown in Table 2 below.
[0288] Polysaccharide fraction from the root of Seokchangpo of Example 2 (mg / g) Constituent sugar content 687.5±3.7 Protein content 0.2±0.0 Flavonoid content 31.6±1.1 Total polyphenol content 23.0±5.0
[0289]
[0290] 1-2-2: Analysis by composition
[0291] The constituent sugars contained in the polysaccharide fraction derived from the roots of Aquilegia japonica according to Example 3 were analyzed three times using a High Performance Anion-Exchange Chromatography (HPAEC) instrument equipped with an amperometric detector and a Pulsed Amperometric Detector (PAD) after hydrolyzing the sugar chains of the sample into monosaccharides. CarboPac PA-1 (250 x 4 mm, Dionex co., USA) was used as a column, and an 18 mM NaOH solution was used as the mobile phase. The flow rate was set to 1.0 mL / min, and the column temperature was 25 ℃. For galacturonic acid and glucuronic acid, the instrument and column conditions were the same, and the mobile phase was analyzed under solvent conditions containing 100 mM NaOAc in 100 mM NaOH. Monosaccharides (fucose, rhamnose, arabinose, galactose, glucose, xylose) were used as standard solutions.
[0292] Example 3: Saturated sugars (mg / g) Fucose 1.1±0.0 Rhamnose 13.4±0.7 Arabinose 91.9±2.9 Galactose 91.6±2.4 Glucose 54.8±1.6 Mannose-xylose 53.7±1.3 Acidic sugars (mg / g) Galacturonic acid 45.7±0.7 Glucuronic acid 7.5±0.3 Total (mg / g) 359.7±8.2
[0293] Looking at Table 3 above, it can be confirmed that the constituent sugars constituting the polysaccharide fraction derived from the roots of Seokchangpo according to Example 3 of the present invention contain neutral sugars at about 85 wt% and acidic sugars at about 15 wt%, and among the neutral sugars, arabinose and galactose each account for about 25 wt% of the constituent sugars, and among the acidic sugars, galacturonic acid accounts for about 13 wt%.
[0294]
[0295] Test Example 4: Animal Experiment
[0296] For statistical analysis of the experiment, one-way ANOVA (Dunnett's test vs. HFD) was used to determine the significant difference in mean values between groups. Significant differences were indicated with * for p values lower than 0.05, ** for p values lower than 0.01, and *** for p values lower than 0.001.
[0297] laboratory animals
[0298] Six-week-old male C57BL / 6J mice raised in a sterile environment were purchased from Joongang Laboratory Animal Co., Ltd. and used. The mice underwent a two-week acclimatization period before the experiment. The mice were raised ad libitum in a breeding room maintained at a temperature of 22±2℃ and a humidity of 40-60% throughout the experiment, and the light-dark cycle was controlled at 12-hour intervals. All animal experiments were conducted in compliance with the Animal Experiment Operation Regulations of the Korea Food Research Institute.
[0299] Sample administration and test group classification
[0300] For sample administration, mice were randomly divided into five groups of nine each. The NC group (normal diet group) was a negative control group fed a normal diet, and the HF group (high-fat diet group, obese control group), FOS group (fructooligosaccharide diet group, positive control group), and sample administration groups were fed high-fat feed ad libitum. The FOS group was orally administered 50 mg / kg of fructooligosaccharide dissolved in sterile saline, and the sample administration groups SFRP5 group (5 mg / kg of polysaccharide fraction derived from Acorus graminearum root) and SFRP10 group (10 mg / kg of polysaccharide fraction derived from Acorus graminearum root) were orally administered the polysaccharide fraction derived from Acorus graminearum root of Example 3 dissolved in sterile saline every day. The NC and HF groups were orally administered the same amount of distilled water for the same period. In order to confirm the anti-obesity effect of the polysaccharide fraction derived from the root of Seokchangpo according to Example 3, body weight was measured at 10:00 am at weekly intervals for a total of 8 weeks starting from the day the diet began.
[0301] In the above, the normal diet used was Ain-93G (Dyets, Bethlehem, PA, USA), and the high-fat diet used was 60% kcal fat (D12492, Research Diets Inc., New Brunswick, NJ, USA).
[0302] [Animal models of five groups]
[0303] Group 1 (NC, negative control group): Normal diet, oral administration of distilled water
[0304] Group 2 (HF, obese control group): high-fat diet, oral administration of distilled water
[0305] Group 3 (FOS, positive control): high-fat diet, oral administration of 50 mg / kg fructo-oligosaccharide
[0306] Group 4 (SFP5, sample administration group): high-fat diet intake, oral administration of 5 mg / kg of polysaccharide fraction derived from the root of Acorus japonica in Example 3
[0307] Group 5 (SFP10, sample administration group): high-fat diet intake, oral administration of 10 mg / kg of polysaccharide fraction derived from the root of Acorus japonica in Example 3
[0308]
[0309] 4-1: Effects on changes in body weight and body fat mass
[0310] Figure 6A is a graph showing the results of measuring the average body weight of animal models divided into Group 1 (NC, negative control group), Group 2 (HF, obese control group), Group 3 (FOS, positive control group), Group 4 (SFP5, 5 mg / kg administration group of the sample of Example 3), and Group 5 (SFP10, 10 mg / kg administration group of the sample of Example 3) for 8 weeks using a body composition analyzer (dual-energy X-ray absorptiometry). At this time, the body composition analyzer was measured according to the protocol using DXA (dual-energy X-ray absorptiometry).
[0311] Looking at A of FIG. 6, it can be confirmed that the NC group (normal diet group) gained 5.90 g of body weight over a total period of 8 weeks, while the HF group (obesity control group) gained 16.10 g of body weight. The FOS group (positive control group) gained 14.10 g of body weight, and the SFP5 and SFP10 groups administered the polysaccharide fraction derived from the root of Acorus coccinea according to Example 3 of the present invention gained 13.39 g and 13.61 g of body weight, respectively, showing an effect of reducing body weight by 11.93%, 13.39%, and 15.47%, respectively, compared to the obese control group. Through the above results, it can be seen that all test groups administered the polysaccharide fraction derived from the root of Acorus coccinea according to Example 3 of the present invention showed a significant decrease in body weight compared to the obese control group (p<0.05).
[0312] Figure 6B is a photograph of the total body shape and abdominal fat density of animal models divided into Group 1 (NC, negative control group), Group 2 (HF, obese control group), Group 3 (FOS, positive control group), Group 4 (SFP5, 5 mg / kg administration group of the sample of Example 3) and Group 5 (SFP10, 10 mg / kg administration group of the sample of Example 3) using a body composition analyzer (dual-energy X-ray absorptiometry) at 8 weeks from the day the diet was started, and Figure 6C is a photograph of the total body shape and abdominal fat density of animal models divided into Group 1 (NC, negative control group), Group 2 (HF, obese control group), Group 3 (FOS, positive control group), Group 4 (SFP5, 5 mg / kg administration group of the sample of Example 3) and Group 5 (SFP10, This is the result of measuring the body fat mass (g) of animal models divided into groups (10 mg / kg administration group of sample 3). In B of Fig. 6, the fat portion among the entire body shape is indicated in red.
[0313] Referring to B of FIG. 6, it can be confirmed that the test groups (groups 4 and 5) that were orally administered the polysaccharide fraction (SFP) derived from the roots of Achyranthes japonica according to Example 3 of the present invention daily for 8 weeks showed a noticeable decrease in the red-marked area corresponding to the fat area compared to the obese control group. In addition, referring to C of FIG. 6, the test groups (SFP10 and 5) that were orally administered the polysaccharide fraction (SFP) derived from the roots of Achyranthes japonica according to Example 3 of the present invention daily for 8 weeks showed an effect of reducing body fat mass by 20.91% compared to the obese control group.
[0314] In summary, it can be seen that the polysaccharide fraction derived from the root of the present invention exhibits significant efficacy in suppressing weight gain and body fat mass increase due to a high-fat diet.
[0315]
[0316] 4-2: Effects on tissue weight changes and glucose tolerance regulation
[0317] Figure 7A is a graph showing the results of measuring the weight of liver tissues extracted from animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3).
[0318] Looking at A of Fig. 7, the weight of liver tissue in the FOS group, SFP5 group, and SFP10 group decreased by 20.66%, 21.49%, and 14.88%, respectively, compared to the HF group (obese control group), and in particular, it can be confirmed that the increase in liver tissue weight in the SFP5 group and SFP10 group administered the polysaccharide fraction derived from the root of Aquilegia japonica according to Example 3 of the present invention was significantly suppressed compared to the obese control group (p<0.05). That is, it was shown that the administration of the polysaccharide fraction derived from the root of Aquilegia japonica of the present invention suppressed fatty liver symptoms induced by a high-fat diet.
[0319] Figure 7B is a graph showing the results of measuring the weight of white epididymal fat tissue by extracting white epididymal fat tissue from animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3).
[0320] Looking at B of FIG. 7, the SFP5 group and the SFP10 group, which were administered the polysaccharide fraction derived from the root of Aquilegia japonica according to Example 3 of the present invention, showed a decrease in the increase in white epididymal fat mass due to a high-fat diet by 18.82% and 19.61%, respectively, compared to the HF group (obese control group), indicating that administration of the polysaccharide fraction derived from the root of Aquilegia japonica suppresses the increase in fat mass due to a high-fat diet in a concentration-dependent manner.
[0321] Figure 7C is a graph showing the results of measuring blood sugar concentrations in animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3).
[0322] Meanwhile, to evaluate whether the polysaccharide fraction derived from the root of Aquilegia japonica of the present invention has the efficacy of improving high-fat diet-induced glucose tolerance impairment, each animal model was fasted for 15 hours prior to the experiment and then subjected to an oral glucose tolerance test (OGTT). Specifically, 2 g / kg of glucose solution was orally administered, and blood glucose levels were measured using a glucometer through tail blood sampling at 0, 30, 60, 90, and 120 minutes.
[0323] Figure 7D is a graph showing the area under the blood glucose curve (AUC) according to the results of an oral glucose tolerance test (OGTT) of an animal model divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3).
[0324] Looking at D of FIG. 7, it can be confirmed that the SFP5 group and the SFP10 group, which were administered the polysaccharide fraction derived from the roots of Seokchangpo according to Example 3 of the present invention, showed a decrease in the area under the blood glucose curve (AUC) due to a high-fat diet by 2.03% and 5.96%, respectively, compared to the HF group (obese control group).
[0325] From the above results, it can be seen that the polysaccharide fraction derived from the root of Aquilegia japonica of the present invention significantly reduces liver weight and fat mass caused by a high-fat diet, and also alleviates glucose tolerance impairment caused by obesity. Therefore, it is expected that the polysaccharide fraction derived from the root of Aquilegia japonica of the present invention will exhibit anti-obesity and anti-diabetic effects.
[0326]
[0327] 4-3: Effects on blood liver function-related enzyme levels (ALT, AST) and blood triglyceride and cholesterol concentrations
[0328] Eight weeks after starting the diet, the animal models divided into Group 1 (NC, negative control group), Group 2 (HF), Group 3 (FOS), Group 4 (SFP5), and Group 5 (SFP10) were fasted for 12 hours, anesthetized using I-Fran solution, and the abdomen and thoracic cavity were incised to collect blood from the portal vein. After coagulation, the serum was separated and used to analyze the concentrations of liver function-related enzymes and serum lipid-related biomarkers.
[0329] For the analysis of ALT (Alanine aminotransferase), AST (Aspartate aminotransferase), and total cholesterol concentrations from the serum, an enzyme-linked immunosorbent assay kit (Cell Biolabs, Inc., Beverly, MA, USA) was used according to the manufacturer's protocol. In addition, for the analysis of blood triglyceride (TG) from the serum, a Triglyceride Colorimetric Assay Kit (Cayman) was used according to the manufacturer's protocol.
[0330] A and B of FIG. 8 are graphs showing the blood ALT and AST concentrations of animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, 5 mg / kg administration group of the sample of Example 3), and group 5 (SFP10, 10 mg / kg administration group of the sample of Example 3), respectively, and C and D of FIG. 8 are graphs showing the blood triglyceride (TG) and total cholesterol (T-Chol) concentrations of animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, 5 mg / kg administration group of the sample of Example 3), and group 5 (SFP10, 10 mg / kg administration group of the sample of Example 3), respectively.
[0331] Looking at A and B of Figure 8, the ALT levels of the SFP5 group and the SFP10 group decreased in a concentration-dependent manner by 42.37% and 45.75%, respectively, compared to the HF group (obese control group) (p<0.05), and the AST levels significantly decreased by 21.72% and 29.55%, respectively, compared to the HF group (obese control group) (p<0.05). That is, it can be seen that the polysaccharide fraction derived from the root of Acorus gramineus of the present invention reduces the levels of ALT and AST increased by a high-fat diet.
[0332] In addition, looking at C and D of Fig. 8, the HF group (obesity control group) showed an increase in both blood triglyceride and total cholesterol concentrations compared to the NC (normal diet group). On the other hand, the SFP5 group and the SFP10 group showed a 17.98% and 21.47% decrease in blood triglyceride concentrations, respectively, compared to the HF group (obesity control group), and the SFP10 group showed a significant 15.05% decrease in blood total cholesterol concentration compared to the HF group (obesity control group) (p<0.05).
[0333] From the above results, it can be seen that the polysaccharide fraction derived from the roots of Seokchangpo of the present invention has excellent efficacy in improving or treating obesity, fatty liver, and dyslipidemia, as it significantly reduces blood ALT and AST levels, which are fatty liver biomarkers increased by a high-fat diet, and blood triglyceride and total cholesterol concentrations, which are lipid level biomarkers.
[0334]
[0335] Test Example 4-4: Effects on liver tissue damage and epididymal fat globules size
[0336] After the above experiment was completed, liver tissue and white epididymal adipose tissue from each experimental group were removed, blood and foreign substances were removed with physiological saline, and the weights were measured. The liver tissue was then stained with H&E to analyze the degree of liver tissue damage, and the white epididymal adipose tissue was stained with H&E to measure the size of fat droplets.
[0337] Figure 9a is a graph showing an image showing the degree of damage in liver tissue and an NAFLD activity score (NAFLD activity score, NAS) based on the images obtained by staining liver tissues extracted from animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3) after H&E staining.
[0338] Looking at Figure 9a, it can be confirmed that the HF group (obesity control group) showed increased liver damage (NAFLD score; degree of liver damage and liver inflammation) compared to the NC (normal diet group). In contrast, both the SFP5 group and the SFP10 group showed a significant decrease in liver damage and liver inflammation by approximately 60% or more compared to the HF group (obesity control group) (p<0.05).
[0339] Figure 9b is an image and graph showing the size of fat globules in epididymal fat tissue, obtained by staining with H&E after extracting epididymal fat tissue from animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3).
[0340] Looking at Figure 9b, it can be confirmed that the HF group (obesity control group) showed an increase in fat globule size due to a high-fat diet compared to the NC group (normal diet group). On the other hand, it can be confirmed that the increase in fat globule size due to a high-fat diet in the SFP5 and SFP10 groups was significantly suppressed compared to the HF group (obesity control group) (p<0.05), and the values were 31.2% and 36.78% lower in the SFP5 and SFP10 groups, respectively, compared to the HF group.
[0341]
[0342] Test Example 5-5: Effects on insulin resistance and fat metabolism
[0343] Blood collected from the portal vein of the animal models divided into Group 1 (NC, negative control group), Group 2 (HF, obese control group), Group 3 (FOS, positive control group), Group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and Group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3) was coagulated, and serum was separated to measure blood insulin concentration, insulin resistance (HOMA-IR), and leptin concentration, which are used as indicators of metabolic disease. Specifically, to measure blood insulin concentration and insulin resistance (HOMA-IR), a kit from Insulin mouse Elisa kit (Invitrogen) was used, and blood leptin hormone concentration for analyzing fat metabolism was measured using a kit from R&D System.
[0344] FIG. 10A is a graph showing blood insulin concentrations of animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, 5 mg / kg administration group of the sample of Example 3), and group 5 (SFP10, 10 mg / kg administration group of the sample of Example 3), and FIG. 10B is a graph showing insulin resistance (HOMA-IR, Homeostatic Model Assessment for Insulin resistance) of animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, 5 mg / kg administration group of the sample of Example 3), and group 5 (SFP10, 10 mg / kg administration group of the sample of Example 3).
[0345] Looking at A of Figure 10, it can be confirmed that the blood insulin concentrations of the SFP5 and SFP10 groups were significantly reduced compared to the obese control group, and the values were reduced by 21% and 36.9%, respectively, compared to the obese control group (p<0.05).
[0346] Looking at B of Figure 10, it can be seen that the HOMA-IR of the SFP5 and SFP10 groups was significantly reduced compared to the obese control group, and the values were reduced by 34.74% and 41.21%, respectively, compared to the obese control group (p<0.05).
[0347] That is, it can be seen that the polysaccharide fraction derived from the root of the present invention can reduce blood insulin concentration and HOMA-IR value.
[0348] Figure 10C is a graph showing the blood leptin hormone concentration of animal models divided into group 1 (NC, negative control group), group 2 (HF, obese control group), group 3 (FOS, positive control group), group 4 (SFP5, group administered 5 mg / kg of the sample of Example 3), and group 5 (SFP10, group administered 10 mg / kg of the sample of Example 3).
[0349] Looking at C of Figure 10, it can be seen that the blood leptin hormone concentration due to a high-fat diet in the HF group (obesity control group) increased compared to the NC (normal diet group). On the other hand, it can be confirmed that the blood leptin hormone concentration due to a high-fat diet in the SFP5 and SFP10 groups significantly decreased compared to the HF group (obesity control group) (p<0.05), and the values were 31.61% and 32.88% lower in the SFP5 and SFP10 groups, respectively, compared to the HF group.
[0350] From the above results, it can be seen that the polysaccharide fraction derived from the root of Seokchangpo of the present invention reduces insulin resistance, which is an indicator of metabolic disease, and reduces the blood leptin hormone concentration, which is related to obesity and lipid metabolism, in a concentration-dependent manner.
[0351] Therefore, it is expected that the polysaccharide fraction derived from the root of the present invention can prevent, improve or treat obesity and metabolic diseases.
[0352]
[0353] Probiotic activity
[0354] Test Example 1-3: Component Analysis of Extracts
[0355] The total dietary fiber content of the hot water extract of the root of Aquilegia japonica prepared according to Example 2 of the present invention was measured, and the results are shown in Table 4 below. In Table 4, the total dietary fiber content was measured at the Food Analysis Research Center of the Korea Food Research Institute using the Food Code Publication No. 2022-48 (June 30, 2022) (Article 8. General Test Methods ▶ 2. Food Component Test Methods ▶ 2.1 General Component Test Methods ▶ 2.1.4 Carbohydrates ▶ 2.1.4.3 Dietary Fiber) - A. Enzyme-Gravimetric Method. All analyses were repeated three times.
[0356] Average dietary fiber content (%) SDRSD Example 2 Acorn root hot water extract 2.10.167.62
[0357] As shown in Table 4, the total dietary fiber content of the hot water extract prepared according to Example 2 of the present invention is 2.1%, indicating that the dietary fiber content is very low.
[0358]
[0359] Test Example 6: Analysis of prebiotic activity of 15 food-derived extracts
[0360] Fifteen food products were selected and screened for food ingredients with prebiotic activity. For prebiotic activity analysis, Lactobacillus bulgaricus, a commercially available probiotic ingredient, was obtained from Mediogen Co., Ltd. Lactobacillus strains were cultured in MRS medium at pH 6.5±0.2 and 37°C for 24 hours.
[0361] For screening, in order to quickly determine the prebiotic activity score for a large number of samples, the proliferation efficacy of Lactobacillus bulgaricus MG5167, a widely used probiotic microorganism, was analyzed according to the following equation 1.
[0362] For the prebiotic activity analysis, the probiotic microorganisms were used in M9 limited medium containing 2 g / L glucose, 0.0005 g thiamin hydrochloride, 0.00735 g calcium chloride, and 0.123 g magnesium sulfate as essential nutrients per 500 mL. Specifically, colonies of the probiotic microorganisms were each spread on MRS solid medium (agar), and primary cultured in a 37 °C incubator for 24-48 hours, and then inoculated into 10 mL of MRS liquid medium (broth) and secondary cultured in a 37 °C incubator for 24-48 hours to prepare a beneficial bacteria culture solution (lactobacillus).
[0363] A new M9 limited medium was inoculated with 5% (v / v) of a culture of beneficial bacteria and samples (glucose, inulin, or 15 food-derived extracts), and the absorbance at 600 nm was measured using a microplate reader at 0 h and every 24 h. The result was then entered into Equation 1 below to calculate the probiotic activity score.
[0364] 1 mg / ml glucose, 1 mg / ml fructooligosaccharide (FOS), 1 mg / ml food-derived hot water extracts (jujube, pawpaw leaves, grape skin, fig, green onion root, corn silk, ice plant, old pumpkin, eggplant, cucumber, lettuce, old pumpkin seed, tomato, Acer monocarpa leaf, Acer monocarpa root (Example 2)) were used as samples. In this case, the food-derived hot water extracts were prepared and used in the same manner as in Example 2, except that jujube, pawpaw leaves, grape skin, fig, green onion root, corn silk, ice plant, old pumpkin, eggplant, cucumber, lettuce, old pumpkin seed, tomato, or Acer monocarpa leaf were used instead of Acer monocarpa root. The control group (CON) used M9 MB medium as a sample.
[0365] [Formula 1]
[0366] prebiotic activity score = [(probiotic log OD on the prebiotic at 24 h)-(probiotic log OD on the prebiotic at 0h)]
[0367] In the above formula,
[0368] *) probiotic log OD on the prebiotic at 24 h is the absorbance measured 24 hours after inoculating the sample (glucose, FOS, or 15 food-derived extracts) into the Lactobacillus culture medium.
[0369] *) probiotic log OD on the prebiotic at 0 h is the absorbance measured 0 hours after inoculating the sample (glucose, FOS, or 15 food-derived extracts) into the Lactobacillus culture medium.
[0370]
[0371] Figure 11 shows the results of analyzing the probiotic activity levels of glucose, FOS, and 15 kinds of food-derived extracts (cilantro, pawpaw leaves, grape skin, fig, green onion root, corn silk, ice plant, old pumpkin, eggplant, cucumber, lettuce, old pumpkin seeds, tomato, Acer monocarpa leaves, Acer monocarpa roots (Example 2)).
[0372] As shown in Fig. 11, the results of comparative analysis of probiotic activity for food-derived extracts at the same concentration of 1 mg / ml confirmed that FOS, which is widely used as a conventional prebiotic material, has a higher proliferation efficacy than glucose, and only the hot water extract of the root of Achyranthes japonica had a superior proliferation efficacy than FOS.
[0373] In particular, it was confirmed that the hot water extract of the root of Seokchangpo increased the proliferation of probiotic microorganisms by about 4 times more than the leaf extract of Seokchangpo, which is widely known as a functional food material with high polyphenol content. In other words, it was confirmed that among the 15 functional food materials, Seokchangpo root had remarkable prebiotic activity.
[0374]
[0375] Test Example 7: Effect of improving intestinal flora (prebiotic activity)
[0376] Strains and culture methods
[0377] To evaluate the improving effect on intestinal microflora, a prebiotic activity score analysis was performed. Lactobacillus bulgaricus MG5167, Lactobalcillus gasseri MG4247, Bifidobacterium longum KCTC3421, and Bifidobacterium bifidum KCTC3440 strains isolated from the human intestine were used as beneficial intestinal bacteria, and were provided by Mediogen Co., Ltd. and the Biological Resource Center. Escherichia coli KCTC2441 was provided by the Biological Resource Center and used as harmful intestinal bacteria.
[0378] Lactobacillus strains were cultured using MRS medium. Culture conditions were pH 6.5±0.2, 37℃, and incubation for 24 hours. The oxygen requirement was facultative anaerobic, and the strains were preserved by freeze-drying or freezing of cell suspensions. Bifidobacteria strains were cultured using TSA medium containing 5% sheep blood and 0.05% L-cysteine at 37℃ for 48-72 hours, and as facultative anaerobes, they were cultured under anaerobic conditions. Escherichia coli strains, a facultative anaerobe, were cultured in TSA medium at 37℃ for 24 hours.
[0379] Prebiotic activity score analysis
[0380] The culture medium for prebiotic activity score analysis was M9 limited medium containing 2 g / L glucose, 0.0005 g thiamin hydrochloride, 0.00735 g calcium chloride, and 0.123 g magnesium sulfate as essential nutrients per 500 mL.
[0381] The colonies of each of the beneficial and harmful bacteria were spread on each MRS solid medium (agar), and cultured for primary use in an incubator at 37°C for 24-48 hours. Then, they were inoculated into 10 ml of MRS liquid medium (broth) and cultured for secondary use in an incubator at 37°C for 24-48 hours to prepare a culture solution of beneficial bacteria (MG5167, MG4247, ACTC3421, or ACTC3440) and a culture solution of harmful bacteria (E. coli).
[0382] Fresh M9 limited medium was prepared and inoculated with 5% (v / v) of a culture of beneficial bacteria (MG5167, MG4247, ACTC3421, or ACTC3440) or a culture of harmful bacteria and the sample (glucose, inulin, or SFRE). After inoculation, the absorbance at 600 nm was measured using a microplate reader at 0 h and every 24 h, and the prebiotic activity score was calculated by substituting the result into Equation 2 below.
[0383] The control group (Normal) is a group to which 5 mg / ml glucose was added as a sample, the positive control group (inulin) is a group to which 5 mg / ml inulin was added as a sample, experimental group 1 (SFRE 0.1%) is a group to which 1 mg / ml Atractylodes root hot water extract (SFRE, Example 2) was added as a sample, and experimental group 2 (SRE 0.5%) is a group to which 5 mg / ml Atractylodes root hot water extract (SFRE, Example 2) was added as a sample.
[0384] [Formula 2]
[0385] Prebiotic activity score = [(probiotic log OD on the prebiotic at 24h - probiotic log OD on the prebiotic at 0h) / (probiotic log OD on glucose at 24h - ptobiotic log OD on glucose at 0h)] - [(enteric log OD on the prebiotic at 24h - enteric log OD on the prebiotic at 0h) / (enteric log OD on glucose at 24h - enteric log OD on glucose at 0h)]
[0386] In the above formula,
[0387] *) probiotic log OD on the prebiotic at 24 h is the absorbance measured 24 hours after inoculation of the sample (inulin or SFRE) into the MG5167, MG4247, ACTC3421, or ACTC3440 culture medium.
[0388] *) probiotic log OD on the prebiotic at 0 h is the absorbance measured 0 h after inoculating the sample (inulin or SFRE) into the MG5167, MG4247, ACTC3421, or ACTC3440 culture medium.
[0389] *) probiotic log OD on glucose at 24h is the absorbance after 24 h of the control group inoculated with glucose in the MG5167, MG4247, ACTC3421, or ACTC3440 culture medium.
[0390] *) probiotic log OD on glucose at 0 h is the absorbance after 0 h of the control group inoculated with glucose in the MG5167, MG4247, ACTC3421, or ACTC3440 culture medium.
[0391] *) Enteric log OD on the prebiotic at 24 h is the absorbance measured 24 hours after inoculating the sample (inulin or SFRE) into the E. coli culture.
[0392] *) Enteric log OD on the prebiotic at 0 h is the absorbance measured 0 hours after inoculating the sample (inulin or SFRE) into the E. coli culture medium.
[0393] *) Enteric log OD on glucose at 24 h is the absorbance of the control group inoculated with glucose in the E. coli culture medium after 24 hours.
[0394] *) Enteric log OD on glucose at 0 h is the absorbance after 0 h of the control group inoculated with glucose in the E. coli culture medium.
[0395]
[0396] pH change analysis
[0397] The pH change of the culture medium was measured before (Before) and 24 hours after (After) the sample was added. The pH change was measured three times using a pH meter (Orion star A211, Thermo Fisher Scientific), and the average value was recorded for analysis.
[0398] Prebiotic activity score analysis results
[0399] Figures 12 to 15 are graphs showing the prebiotics activity scores of experimental group 1 (0.1%), experimental group 2 (0.5%), positive control group (Inulin), and normal group (Normal) for Lactobacillus bulgaricus MG5167, Lactobalcillus gasseri MG4247, Bifidobacterium longum KCTC3421, or Bifidobacterium bifidum ACTC3440.
[0400] Figure 12 shows the results for Lactobacillus bulgaricus MG5167, Figure 13 shows the results for Lactobalcillus gasseri MG4247, Figure 14 shows the results for Bifidobacterium longum KCTC3421, and Figure 15 shows the results for Bifidobacterium bifidum ACTC3440.
[0401] As shown in Figures 12 to 15, the results of evaluating the proliferative ability of beneficial bacteria compared to harmful bacteria, E. coli, showed that the hot water extract of the root of Seokchangpo (SFRE) of Example 2 according to the present invention had superior prebiotic activity against Lactobacillus and Bifidobacterium strains compared to the untreated control group (Normal).
[0402] The hot water extract of the root of Seokchangpo was confirmed to have excellent prebiotic activity scores against Lactobacillus bulgaricus MG5167, Lactobalcillus gasseri MG4247, Bifidobacterium longum KCTC3421, and Bifidobacterium bifidum ACTC3440.
[0403] The present invention's Sophora japonica root hot water extract (SFRE) was confirmed to have a prebiotic activity of 2.4 times, 1.6 times, 1.9 times, and 1.4 times higher, respectively, for Lactobacillus bulgaricus MG5167, Lactobalcillus gasseri MG4247, Bifidobacterium longum KCTC3421, and Bifidobacterium bifidum ACTC3440 when added at 0.5 mg / ml (0.5%) rather than 0.1 mg / ml (0.1%), compared to inulin, a representative functional material related to improving intestinal function.
[0404] In summary, it was confirmed that the hot water extract of the root of the present invention has a high proliferation activity against four types of intestinal beneficial bacteria when compared to the control group, and when compared to the positive control inulin, it was confirmed that when 0.5 mg / ml (0.5%) was added, it showed a significantly higher prebiotic activity score against four types of strains (Lactobacillus bulgaricus MG5167, Lactobalcillus gasseri MG4247, Bifidobacterium longum KCTC3421, and Bifidobacterium bifidum ACTC3440). Therefore, the composition of the present invention including it as an active ingredient inhibits the proliferation of harmful intestinal bacteria while increasing the proliferation of beneficial bacteria, thereby inhibiting the proliferation of Lactobacillus It can be usefully used as a prebiotic composition for Lactobacillus bulgaricus MG5167, Lactobalcillus gasseri MG4247, Bifidobacterium longum KCTC3421 and Bifidobacterium bifidum ACTC3440.
[0405] pH change analysis results
[0406] The pH changes for experimental group 1 (0.1%), experimental group 2 (0.5%), positive control group (Inulin), and normal group (Normal) were measured and shown in Table 5.
[0407] Control group (Normal) Positive control group (Inulin) Example 2 Acorus bulgaricus root hot water extract (SFRE) 0.1% 0.5% 0 h24 h0 h24 h0 h24 h0 h24 h L. bulgaricus 6.7±0.06.7±0.16.8±0.06.3±0.16.8±0.36.3±0.46.7±0.25.9±0.1 L. gasseri 6.8±0.16.7±0.16.8±0.16.4±0.16.8±0.26.7±0.26.7±0.26.3±0.1B. longum6.6±0.16.3±0.16.6±0.15.5±0.26.5±0.15.4±0.36.6±0.24.5±0.1B. bifidum6.8±0.16.7±0.06.9±0.16.2±0.16.8±0.15.4±0.26.7±0.15.1±0.2
[0408] As shown in Table 5, no significant pH changes were observed in the control and positive control groups before (0 h) and after (24 h) incubation (a significant decrease was observed in the positive control group for the Bifidobacterium longum culture, but this was at the same level as the concentration of 0.1 mg / ml of the Seokchangpo root hot water extract).
[0409] On the other hand, when 1 mg / ml of Seokchangpo root hot water extract was added, it was confirmed that the pH of the Bifidobacterium longum KCTC3421 and Bifidobacterium bifidum ACTC3440 cultures significantly decreased to weak acidity.
[0410] When 5 mg / ml of Seokchangpo root hot water extract was added, it was confirmed that the pH of the culture solution of Lactobacillus bulgaricus MG5167, Bifidobacterium longum KCTC3421, and Bifidobacterium bifidum KCTC3440 strains significantly decreased to slightly acidic.
[0411] In other words, unlike inulin, the Aquilegia japonica root water extract promotes the production of short-chain fatty acids (SCFAs) from beneficial bacteria. The Aquilegia japonica root water extract can provide health benefits that cannot be expected from inulin, such as serving as an energy source for intestinal epithelial cells, strengthening the immune system, and regulating metabolism. Unlike other prebiotics, the Aquilegia japonica root water extract maintains a slightly acidic environment, and thus has a significantly superior effect in inhibiting the growth of harmful bacteria. Therefore, it can be effectively used to improve intestinal flora.
[0412]
[0413] Test Example 8: Treatment Effect on Leaky Gut Syndrome
[0414] laboratory animals
[0415] Forty-five 6-week-old male C57BL / 6J mice, raised in a sterile environment, were purchased from Joongang Laboratory Animal Co., Ltd. Mouse rearing conditions were maintained at a temperature of 22±2°C and a humidity of 40-60%, with a light-dark cycle of 12-hour intervals. Experiments were conducted after a one-week adaptation period.
[0416] Sample administration and sampling
[0417] For sample administration, mice were randomly divided into five groups of nine each. The NC (normal group) was a negative control group fed a normal diet, and the HF (high fat diet group), positive control group, and sample administration groups were fed a high-fat diet (Modified AIN 76A purified rodent diet (60 cal% fat)) with added lard to increase calories by 60 cal%.
[0418] The positive control group (PC) was administered 50 mg / kg of inulin orally daily, sample SFRE-50 was administered 50 mg / kg of the Aquilegia japonica root water extract of Example 2 orally daily, sample SFRE-100 was administered 100 mg / kg of the Aquilegia japonica root water extract of Example 2 orally daily, and the negative control group and HF were administered the same amount of distilled water orally for the same period. Body weight was measured every week at 10:00 am for a total of 8 weeks. After the 8-week experimental period, intestinal permeability, intestinal pH, and length were analyzed after fasting for 12 hours.
[0419] Animal models of five groups
[0420] Group 1 (NC, negative control group): normal diet, oral administration of distilled water
[0421] Group 2 (HF, high-fat diet group): high-fat diet intake, oral administration of distilled water
[0422] Group 3 (PC, positive control group): high-fat diet, oral administration of 50 mg / kg inulin
[0423] Group 4 (SFRE-50): High-fat diet, oral administration of 50 mg / kg of the hot water extract of the root of Atractylodes japonica of Example 2
[0424] Group 5 (SFRE-100): High-fat diet, oral administration of 100 mg / kg of the hot water extract of the root of Atractylodes japonica of Example 2
[0425] Analysis of the effects of leaky gut syndrome
[0426] After oral administration of 400 mg / kg of FITC-dextran to experimental animals in groups 1 to 5, tail vein blood collection was performed 0, 2, and 4 hours later. 100 μl of the obtained blood was centrifuged (12,000 × g, 10 min, 4 °C), and the supernatant was recovered. The absorbance was measured using a microplate reader with an excitation wavelength of 485 nm and an emission wavelength of 535 nm. The concentration was calculated using the standard curve of FITC-dextran, and the FITC-dextran concentration by time point was expressed as the area under the curve (AUC).
[0427] Intestinal pH and length analysis
[0428] Experimental animals in groups 1 to 5 were anesthetized using I-Fran solution, and the abdomen and thoracic cavity were incised to extract intestinal tissue from each experimental animal and measure its length. At this time, 5 mL of sterile water was injected into the intestine twice to recover the intestinal contents and analyze them using a pH meter.
[0429] Analysis of intestinal tight junction protein expression levels
[0430] Experimental animals from groups 1 to 5 were anesthetized using IFRAN solution, and the abdomen and thoracic cavity were incised to extract intestinal tissue from each experimental animal. At this time, 5 mL of sterile water was injected twice into the intestine to recover the intestinal contents, and then the tissue was ground and analyzed by Western blot to analyze the expression of intestinal tight junction proteins. Tight junction genes are proteins that play a role in the junction between epithelial cells in the intestine, and this is translated into the expression of ZO-1, Occludin, and Claudin-1 genes. The expression levels of ZO-1, Occludin, and Claudin-1 by the hot water extract of the root of Achyranthes japonica were measured by Western blot.
[0431] The harvested cells were lysed in mammalian protein extraction buffer (Sigma Chemical Co., St. Louis, MO, USA) in the presence of protease inhibitor cocktail (Sigma) and phenylmethanesulfonyl fluoride (Sigma, PMSF). The lysate was centrifuged at 12,000 rpm for 20 min at 4°C, and the protein content was determined using protein assay dye reagent concentrate (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions. The proteins were fractionated by SDS-polyacrylamide gel electrophoresis and then electrophoretically transferred to nitrocellulose blotting membranes (Amersharm, GE Healthcare Life science, Germany). Anti-occludin (1:1000; Invitrogen, USA), anti-claudin-1 (1:1000; Invitrogen), anti-ZO-1 (1:1000; Invitrogen), and anti-β-actin (1:2500; Abcam, Cambridge, UK) antibodies were used in the above analysis. Protein bands were visualized by enhanced chemiluminescence using the ELC kit (Millipore, USA), and bands were quantified by Quantity 1 version 4.6.7 software (Bio-Rad Laboratories, Hercules, CA, United States).
[0432] Statistical analysis
[0433] For statistical analysis of the experiment, one-way ANOVA (Dunnett's test vs. HFD) was used to determine significant differences in mean values between groups.
[0434]
[0435] Figure 16 is a graph (a) showing the amount of FITC-dextran transferred into the blood 2 and 5 hours after oral administration of FITC-dextran in a fasting state 8 weeks after ingestion of the negative control group (NC), high-fat diet group (HF), positive control group (PC), group 4 (SFRE-50), and group 5 (SFRE-100) for intestinal permeability analysis, and Figure 16b is a graph (b) showing the quantification of this and comparison of intestinal permeability.
[0436] As shown in Figure 16, compared to the negative control group (NC) of 100%, the high-fat diet group (HF) showed a significant increase in intestinal permeability of 175% through the high-fat diet, which can be seen to have caused leaky gut syndrome.
[0437] The positive control group (PC) was administered inulin simultaneously with a high-fat diet, and intestinal permeability was confirmed to be 142%, which was a 33% decrease compared to the high-fat diet group.
[0438] In the case of the Aquilegia chinensis root water extract (SFRE), intestinal permeability was measured to be 121% and 117% at concentrations of 50 mg / kg and 100 mg / kg, respectively, and it was confirmed that it was significantly reduced by 54% and 58% compared to the high-fat diet group. That is, since the Aquilegia chinensis root water extract (SFRE) was found to reduce intestinal permeability in a concentration-dependent manner, it was confirmed that the Aquilegia chinensis root water extract suppresses intestinal permeability increased by a high-fat diet to the level of a normal group, resulting in the prevention, improvement, or treatment of leaky gut syndrome that causes various diseases. Therefore, the Aquilegia chinensis root water extract according to the present invention, particularly the composition comprising 50 mg / kg or more of the Aquilegia chinensis root water extract as an active ingredient, can be used for the purpose of improving, preventing, or treating leaky gut syndrome.
[0439]
[0440] Figure 17 is a graph showing the results of measuring the intestinal pH of the negative control group (NC), high-fat diet group (HF), positive control group (PC), group 4 (SFRE-50), and group 5 (SFRE-100). According to this graph, the pH of the negative control group (NC), which has a normal intestinal environment, was confirmed to be 6.9. Considering that the pH of a healthy intestine is 7.0, it can be seen that this is a similar value.
[0441] On the other hand, it was confirmed that the intestinal pH of the high-fat diet group (HF) significantly increased to 7.5. The positive control group (PC) with added inulin improved to a slightly acidic condition of pH 6.5, and SFRE-50 and SFRE-100 administered with the hot water extract of the root of Acorus coccidioides also significantly decreased to pH 6.9 and 6.8, respectively. This was at the level of the negative control group (NC), and it was confirmed that by suppressing the intestinal environment that changes to an acidic condition due to a high-fat diet and maintaining it as slightly acidic, it improves intestinal function such as suppressing the growth of harmful bacteria that produce endotoxins and promoting calcium absorption, resulting in the prevention, improvement, or treatment of leaky gut syndrome.
[0442] Through the above-described results, it can be seen that the Seokchangpo root hot water extract according to the present invention, particularly the composition comprising 50 mg / kg or more of Seokchangpo root hot water extract as an active ingredient, has uses for improving, preventing, or treating not only leaky gut syndrome but also intestinal function.
[0443]
[0444] Figure 18 is a graph showing the results of measuring the intestinal length of the negative control group (NC), high-fat diet group (HF), positive control group (PC), group 4 (SFRE-50), and group 5 (SFRE-100).
[0445] In general, when high-fat foods are consumed for a long period of time or when intestinal inflammation occurs, the intestinal environment collapses, and the intestinal length becomes shorter than normal. In this experiment, it was confirmed that the intestinal length of the high-fat diet group (HF) was reduced by approximately 15% compared to the negative control group (NC). On the other hand, when the hot water extract of Acorus gramineus root was consumed daily at 100 mg / kg, the intestinal length was significantly restored by 10%. Therefore, it was confirmed that it prevents, improves, or treats leaky gut syndrome by suppressing the collapse of the intestinal environment caused by a high-fat diet and restoring the reduced intestinal length.
[0446]
[0447] Figure 19 is a graph showing the results of Western blot analysis of the expression levels of adhesion proteins in the intestinal tissues of the negative control group (NC), high-fat diet group (HFD), group 4 (SRE-50), and group 5 (SRE-100).
[0448] As shown in Figure 19, long-term consumption of a high-fat diet (HFD) causes inflammation in the intestines and reduces the expression of intestinal adhesion proteins. In this experiment, it was confirmed that the expression of ZO-1 and Occludin was reduced in the high-fat diet (HFD) group compared to the negative control (NC) group.
[0449] On the other hand, when the hot water extract of the root of Seokchangpo was consumed daily at 100 mg / kg, the expression levels of the adhesion protein were significantly increased by 60%, 34%, and 64%, respectively. This confirmed that it suppresses the breakdown of the intestinal environment caused by a high-fat diet, increases the expression of the adhesion protein, and prevents, improves, or treats leaky gut syndrome.
[0450]
[0451] Through the above-described results, it can be seen that the composition comprising the hot water extract of the root of Seokchangpo according to the present invention, particularly the hot water extract of the root of Seokchangpo in an amount of 50 mg / kg, more preferably 100 mg / kg or more as an active ingredient, has a use for improving, preventing or treating leaky gut syndrome.
[0452]
[0453] Below, a formulation example of a composition containing the hot water extract of the root of Seokchangpo of the present invention or a fraction thereof is described, but the present invention is not intended to be limited thereto, but is merely intended to be described in detail.
[0454]
[0455] Preparation Example 1. Preparation of a powder
[0456] 500 mg of the extract of Seokchangpo or its fraction obtained in the example
[0457] 100 mg of lactose
[0458] 10 mg of talc
[0459] The above ingredients are mixed and filled into a sealed bag to prepare a powder.
[0460]
[0461] Preparation Example 2. Preparation of tablets
[0462] 300 mg of the extract of Seokchangpo or its fraction obtained in the example
[0463] 100 mg of corn starch
[0464] 100 mg of lactose
[0465] Magnesium stearate 2 mg
[0466] After mixing the above ingredients, tablets are manufactured by pressing them according to the usual tablet manufacturing method.
[0467]
[0468] Preparation Example 3. Preparation of capsules
[0469] 200 mg of the extract of Seokchangpo or its fraction obtained in the example
[0470] 3 mg of crystalline cellulose
[0471] Lactose 14.8 mg
[0472] Magnesium stearate 0.2 mg
[0473] The above ingredients are mixed according to the conventional capsule manufacturing method and filled into a gelatin capsule to manufacture a capsule.
[0474]
[0475] Preparation Example 4. Preparation of Injectable
[0476] 600 mg of the extract of Seokchangpo or its fraction obtained in the example
[0477] Mannitol 180 mg
[0478] 2974 mg of sterile distilled water for injection
[0479] Na2HPO4,12H2O 26 mg
[0480] It is manufactured with the above ingredient content per ampoule according to the manufacturing method of a conventional injection.
[0481]
[0482] Preparation Example 5. Preparation of liquid preparation
[0483] 4 g of the extract of Seokchangpo or its fraction obtained in the example
[0484] 10 g of isoflavonoids
[0485] 5 g of mannitol
[0486] Appropriate amount of purified water
[0487] According to the usual method of manufacturing a liquid, each ingredient is added to purified water and dissolved, an appropriate amount of lemon flavor is added, the above ingredients are mixed, purified water is added, and the total amount is adjusted to 100 g, then filled into a brown bottle and sterilized to manufacture a liquid.
[0488]
[0489] Preparation Example 6. Preparation of granules
[0490] 1,000 mg of the extract of Seokchangpo or its fraction obtained in the example
[0491] Vitamin mixture appropriate amount
[0492] Vitamin A acetate 70 μg
[0493] Vitamin E 1.0 mg
[0494] Vitamin B1 0.13 mg
[0495] Vitamin B2 0.15 mg
[0496] Vitamin B6 0.5 mg
[0497] Vitamin B12 0.2 μg
[0498] Vitamin C 10 mg
[0499] 10 μg of biotin
[0500] Nicotinamide 1.7 mg
[0501] 50 μg of folic acid
[0502] Calcium pantothenate 0.5 mg
[0503] Appropriate amount of mineral mixture
[0504] 1.75 mg of ferrous sulfate
[0505] 0.82 mg of zinc oxide
[0506] Magnesium carbonate 25.3 mg
[0507] 15 mg of monobasic potassium phosphate
[0508] 55 mg of dibasic calcium phosphate
[0509] Potassium citrate 90 mg
[0510] 100 mg of calcium carbonate
[0511] Magnesium chloride 24.8 mg
[0512] The composition ratio of the above vitamin and mineral mixture is a preferred example of mixing ingredients relatively suitable for granules, but the mixing ratio may be arbitrarily modified, and the above ingredients may be mixed according to a conventional granule manufacturing method, and then granules may be manufactured and used in the manufacture of a health functional food composition according to a conventional method.
[0513]
[0514] Preparation Example 7. Manufacturing of functional beverages
[0515] 1,000 mg of the extract of Seokchangpo or its fraction obtained in the example
[0516] 1,000 mg of citric acid
[0517] 100 g of oligosaccharide
[0518] 2 g of plum concentrate
[0519] 1 g of taurine
[0520] Add purified water to make a total of 900 ml
[0521] The above ingredients are mixed according to a conventional health beverage manufacturing method, then stirred and heated at 85°C for about 1 hour, the resulting solution is filtered, placed in a sterilized 2 L container, sealed and sterilized, and then stored in a refrigerator, and then used to manufacture the functional beverage composition of the present invention.
[0522] The above composition ratio is a preferred example of a mixture of ingredients relatively suitable for a preferred beverage, but the mixing ratio may be arbitrarily modified according to regional and national preferences such as demand class, demand country, and intended use.
[0523]
[0524] Although the present invention has been described with reference to the preferred embodiments mentioned above, various modifications and variations are possible without departing from the spirit and scope of the invention. Furthermore, the appended claims encompass such modifications and variations as fall within the spirit of the present invention.
Claims
1. A food composition for enhancing immune function or preventing or improving obesity or metabolic disease, containing an extract of Seokchangpo or a fraction thereof as an active ingredient.
2. In paragraph 1, A food composition characterized in that the above-mentioned Seokchangpo extract is extracted with water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
3. In paragraph 1, A food composition characterized in that the above-mentioned Seokchangpo extract contains 0.1% to 2.5% of dietary fiber.
4. In paragraph 1, A food composition characterized in that the above-mentioned Seokchangpo fraction is a polysaccharide fraction derived from Seokchangpo.
5. In paragraph 4, A food composition characterized in that the polysaccharide fraction derived from the above Seokchangpo comprises 20 to 35 wt% of neutral sugar, 1 to 10 wt% of acidic sugar, and 1 to 5 wt% of polyphenol relative to the total polysaccharide fraction.
6. In paragraph 5, A food composition characterized in that the polysaccharide fraction derived from the above Seokchangpo further contains 1 to 5 wt% of flavonoids.
7. In paragraph 4, A food composition characterized in that the constituent sugars constituting the polysaccharide fraction derived from the above Seokchangpo include 80 to 90 wt% of neutral sugar and 10 to 20 wt% of acidic sugar.
8. In paragraph 7, A food composition characterized in that the above-mentioned composition contains neutral sugar and acid sugar in a weight ratio of 1:0.1 to 1.
9. In paragraph 7, The above neutral sugars are composed of fucose, rhamnose, arabinose, galactose, glucose and xylose; A food composition characterized in that the acidic sugar is composed of galacturonic acid and glucuronic acid.
10. In paragraph 9, A food composition characterized in that the arabinose and galactose are each contained in the constituent sugars at 20 to 30 wt%.
11. In paragraph 4, A food composition characterized in that the polysaccharide fraction derived from Seokchangpo is prepared by a method comprising: (a) a step of mixing an extraction solvent with Seokchangpo powder and performing a first extraction at 70 to 100°C; (b) a step of precipitating the first extracted extract with a C1 to C4 alcohol and recovering the precipitate; and (c) a step of recovering a fraction having a molecular weight exceeding 12 kDa from the precipitate.
12. In paragraph 1, A food composition characterized in that the composition is a prebiotic composition.
13. In paragraph 12, The above composition has prebiotic activity that relatively increases beneficial intestinal bacteria compared to harmful intestinal bacteria. The above intestinal beneficial bacteria are at least one selected from the group consisting of Lactobacillus bulgaricus, Lactobalcillus gasseri, Bifidobacterium longum, and Bifidobacterium bifidum. A food composition characterized in that the above intestinal harmful bacteria is Escherichia coli.
14. In paragraph 12, The above composition is a food composition characterized in that it promotes the proliferation of beneficial bacteria and the production of short-chain fatty acids (SCFA) in the intestines of a living organism.
15. In paragraph 1, A food composition characterized in that the metabolic disease is at least one selected from dyslipidemia, non-alcoholic fatty liver disease, insulin resistance syndrome, and diabetes.
16. A prebiotic composition comprising a Seokchangpo extract or a fraction thereof as an active ingredient.
17. A food composition for preventing or improving leaky gut syndrome, comprising an extract of Seokchangpo or a fraction thereof as an active ingredient.
18. In paragraph 17, The above composition is a food composition characterized in that it improves the intestinal environment destroyed by a high-fat diet, restores intestinal beneficial microorganisms, reduces increased intestinal mucosal permeability, and restores reduced intestinal length.
19. A pharmaceutical composition for preventing or treating diseases caused by weakened immunity, comprising an extract of Seokchangpo or a fraction thereof as an active ingredient.
20. A pharmaceutical composition for preventing or treating obesity or metabolic disease, comprising an extract of Seokchangpo or a fraction thereof as an active ingredient.
21. In paragraph 20, A pharmaceutical composition characterized in that the metabolic disease is at least one selected from dyslipidemia, non-alcoholic fatty liver disease, insulin resistance syndrome, and diabetes.
22. A pharmaceutical composition for preventing or treating leaky gut syndrome, comprising an extract of Atractylodes japonica or a fraction thereof as an active ingredient.
23. In paragraph 22, The above composition is a pharmaceutical composition characterized in that it improves the intestinal environment destroyed by a high-fat diet, restores intestinal beneficial microorganisms, reduces increased intestinal mucosal permeability, and restores reduced intestinal length.
Citation Information
Patent Citations
Treatment of diabetes comprising extract of Acori Graminei Rhizoma and pharmaceutical preparation containing the same
KR1020040049959A
Acous gramineus soland extract for preventing andtreating ischemic heart disease and pharmaceuticalcomposition and health food containing the same
KR1020050117024A
Composition for treating and preventing neurodegenerative disorders which includes acorus gramineus solander extract
KR1020140024496A
